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Cost and cost savings have become an important focus for health policy administrators.
However, there are missing pieces in our approach to cost analysis; there is no consensus on
multivariable methods, no indicators of minimally acceptable values, and no specification of
process costing.
In this dissertation, I propose to fill the gaps in the literature by 1) identifying which
methods are appropriate for large claims data, 2) examine existing methods to establish
minimally important difference (MID) in health outcomes to identify MID in costs, and 3)
determine differences in sick visit clinic costs using a modified micro-costing method.
Most models that were compared to the generalized linear models Gamma distribution
with log link found it to be the superior model in both simulated data and real administrative
data. We recommend that in cases where acceptable anchors are not available to establish an
MID, both the Delphi and the distribution-method of MID for costs be explored for convergence.
Our micro-costing approach is feasible to use under virtual working conditions; requires minimal
provider time; and generates detailed cost estimates that have “face validity” with providers and
are relevant for economic evaluation.
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CHAPTER 1
INTRODUCTION

The United States (US) has one of the highest annual growth rates for healthcare
spending in the world, outpacing the gross domestic product (GDP) deflator by almost 5%,
indicating that the increase in health care costs are more than what can be accounted for
by inflation (Kaiser Family Foundation, 2011; Claxton, Rae, Levitt, & Cox, 2018; Zilberberg
& Shorr, 2010). Concern about the growing spending trend in healthcare has prompted
clinical and health policy decision makers to continually assess benefits and value of new
treatments and care processes with an objective to control costs without sacrificing the
quality of care. Tasked with the need to efficiently allocate limited resources, decision
makers must consider the impact of money spent on one resource compared to the benefit
that same money could achieve if it were spent on other resources (Zilberberg & Shorr,
2010; Weinstein, Siegel, Gold, Kamlet, & Russell, 1996; Gammon & Cotten, 2016; Tan,
Rutten, van Ineveld, Redekop, & Roijen, 2009; Sanders, et al., 2016; Shander, et al.,
2010).
The US is increasingly focusing on value of care, of which cost is an essential
component. However, there are missing pieces in our approach to cost analysis; there is
no consensus on multivariable methods, no indicators of minimally acceptable values, and
no specification of process costing.
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1.1. BACKGROUND
1.1.1 Multivariable methods in cost analysis
Cost and cost savings are becoming increasingly important for the US healthcare
system. During the first 5 months of 2019, over one hundred papers with a key word of
“cost savings” were published in major US journals. This overwhelming focus on cost
savings makes it imperative that we begin to standardize our approach to cost analysis,
because different approaches have different underlying statistical assumptions and often
result in different outcomes.
Appropriate health care cost estimation is crucial as it is used to guide evidencebased health policy implementation. Health policy makers rely on costs to drive their
decisions (Power & Eisenberg, 1998). The estimation for costs associated with a disease,
such as diabetes, can influence the allocation of resources for the prevention and
treatment of the disease (Fukuda, Ikeda, Shiroiwa, & Fukuda, 2016). As numerous
administrative data sources have become available for analysis, it is essential that these
data are analyzed properly. These claims data, or billing data, are usually observational
data sources, such as Medicare billing data, that are often assessed for health care cost
outcomes. Inaccurate cost analysis can lead policy makers to make sub-optimal decisions.
1.1.2 Minimally acceptable values
The determination of a minimally acceptable difference for clinical measures can
be easily assessed through repeated use and clinician experience from observations of
the outcomes to identify what is clinically important. Unfortunately, for more subjective
outcomes, such as quality of life, the determination of a minimally acceptable difference
requires an interpretation that can be understood by clinicians to judge effect of
magnitude.
Minimal clinically important difference (MCID) was developed by Jaeschke, Singer,
Guyatt (Jaeschke, Singer, & Guyatt, 1989) to create interpretability of change in score of
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Quality of Life (QOL) Questionnaires in the “most influential paper in MID history” (King,
2011). Jaeschke et al. defined MCID, or as later referred to as minimally important
difference (MID), as the “the smallest difference in score in the domain of interest which
patients perceive as beneficial and which would mandate, in the absence of troublesome
side effects and excessive cost, a change in the patient’s management” (Jaeschke,
Singer, & Guyatt, 1989). There are three methods to determine MCID: anchor-based,
distribution-based, and consensus-based.
MIDs have been established to be useful for planning studies using quality of life
and clinical assessment tools. These areas use guiding rules for MID to judge effect
magnitude, however, we have found no publications establishing a MID for costs.
1.1.3.1 Process costing of value of care
As healthcare costs increase at alarming rates, there is a need to have accurate
information when making decisions based on the value (cost-effectiveness) of health
interventions and health care processes. Decision makers must determine the most
efficient allocation of limited resources while delivering the best quality of care. Typically
cost analysis is evaluated within an organization using the hospital internal accounting
system, a system that is developed to maximize profitability and may not be representative
of the true costs of care (Carroll & Lord, 2016; Zilberberg & Shorr, 2010). Nonetheless,
these costing results often guide the decision-making about health care process. Better
costing methods are therefore needed to provide a more accurate cost analysis to make
better informed decisions. Time-driven activity-based costing (TDABC) is a less frequently
used, but more accurate, micro-costing methodology that identifies true costs using
service specific activity and resource use evaluated with patient specific treatment times
(Gammon & Cotten, 2016; Carroll & Lord, 2016; Tan, Rutten, van Ineveld, Redekop, &
Roijen, 2009). The TDABC method has been used to identify areas for process
improvement, though, it has not always been cost efficient to perform (Shander, et al.,
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2010). The biggest barrier to implementing TDABC is that it is resource intensive; requiring
research staff with expertise to know what to assess to be present in the clinic to observe
and record the care processes of each patient using a stopwatch to manually collect the
timing of processes and resource use.
1.1.3.2 Electronic Health Records and Value Measurement
Heath care systems have taken an interest in the secondary use of electronic
health records (EHR) for data as a cost-effective alternative to evaluate quality and
efficiency of processes. The use of EHR timestamps have been established as a feasible
and valid source for accurate data (Wu, et al., 2017) and its versatility as a resource is
demonstrated by the various ways recent studies have utilized its secondary use. EHR
time logs have been used to assess efficiency in workflow models and identify areas for
process improvement, as well as, evaluate quality of care processes and determine when
care deviates from usual process of care (Zhang, Mehotra, Liebovitz, Gunter, & Malin,
2013; Karp, Freeman, Simpson, & Simpson, 2018; Chen, et al., 2015).
1.2. PROBLEM STATEMENT
The literature has demonstrated limited research in the approach to cost analysis. These
gaps are evident in existing publications regarding costs. This project will establish better
methods to address these gaps in the literature.
1.2.1 Problem Statement 1
The analysis of large observational datasets come with its own challenges. The
data are often skewed and group comparisons often bias. Cost data are commonly
positively skewed with a few outlying patients, often with complications or very ill,
disproportionately consisting of much of the total costs (Dodd, Bassi, Bodger, &
Williamson, 2006; Bohl, Blough, Fishman, Harris, & Phelan, 2013; Malehi, Pourmotahari,
& Angali, 2015; Kurz, 2017). Administrative data can often include zero costs or zero
observations (non-users) that may make up a large proportion of the data (Malehi,
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Pourmotahari, & Angali, 2015; Kurz, 2017). Further challenges arise when analysis of cost
data also need to consider censored data within the research time frame (Dodd, Bassi,
Bodger, & Williamson, 2006). Healthcare cost can vary according to region, health care
system, population, and payer; thus, adjustment of costs is needed for comparisons
across these factors. There are many different methods currently being used to estimate
costs including: generalized linear models with a log link, natural logarithm transformed
costs, gamma distribution, two-part models, and Bayesian models. As cost drives many
health care policies, inaccurate analyses of cost can have serious consequences. A
review of the current state of the evidence is needed to determine which approach is
appropriate and valid, without which we cannot judge the quality of approaches being used
in current studies.
1.2.2 Problem Statement 2
Studies to assess costs are abounding but their design and planning is hampered
by the lack of indicators of magnitude of an important effect size for costs incurred in
different settings. Other areas, such as quality of life measurement, use guiding rules for
minimally important difference (MID) to judge effect magnitude. MIDs are useful for
planning studies using quality of life and clinical assessment tools. However, we have
found no publications establishing a MID for costs.
1.2.3 Problem Statement 3
Better costing methods are needed to provide a more accurate cost analysis to
make better informed decisions. Time-driven activity-based costing (TDABC) is a less
frequently used, but more accurate, micro-costing methodology that more accurately
identifies costs using service specific activity and resource use evaluated with patient
specific treatment times (Gammon & Cotten, 2016; Carroll & Lord, 2016; Tan, Rutten, van
Ineveld, Redekop, & Roijen, 2009). The TDABC method has been used to identify areas
for process improvement, though, it has not always been cost efficient to perform
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(Shander, et al., 2010). The biggest barrier to implementing TDABC is that it is resource
intensive; requiring research staff present in the clinic to observe and record the care
processes of each patient using a stopwatch to manually collect the timing of processes
and resource use. A solution to this shortcoming could be through use of electronic health
records (EHR), providing a more efficient approach to record times of the sequence of
events via electronic time stamps to implement TDABC. EHR activity logs have been
effectively utilized to evaluate quality and efficiency of workflow and process of care
(Mans, et al., 2008; Chen, et al., 2015; Wu, et al., 2017).
1.3. RESEARCH HYPOTHESES
1.3.1 Research Question 1
What methods of cost analysis are statistically and mathematically appropriate to use with
large claims data and is there one method that could be considered optimal?
1.3.2. Research Question 2
Can existing methods to determine minimally important differences in health outcomes be
used to identify minimally important differences in costs?
1.3.3. Research Question 3
Will the pediatric sick visit weighted labor cost, estimated using a modified TDABC, for a
clinic visit before the COVID-19 pandemic show a difference in mean cost than a clinic
visit during the COVID-19 pandemic?
Aim 1
Use structured provider interviews to identify the major variations in patient flow and
describe the care process and resource use using TDABC workflow diagrams with time
indicators for a moderate complexity visit for an established patient.
Aim 2
Compare providers' minute estimates to minutes estimated from EHR time stamps from
telehealth "dashboard" data, and from Clarity EHR data, and estimate the uncertainty in
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minute values using distributional parameters derived from CMS CPT standards and
Monte-Carlo simulations for 100,000 visits to estimate uncertainty in labor cost estimates.
Aim 3
Aggregate flow chart estimates and uncertainty measures in a decision tree and calculate
visit labor costs for an in-person sick visit before COVID-19 to a sick visit during the
COVID-19 pandemic.
H1: Mean weighted labor cost before COVID - Mean weighted labor cost during
COVID is < the MID defined by the anchor method as a difference between mean
payment for adjacent CPT codes
1.4. DEFINITION OF TERMS
US = United States
GDP = gross domestic product
TDABC = time-driven activity-based costing
PA = Physician assistant
EHR = Electronic health record
MID = minimally important difference
MCID = Minimal clinically important difference
QOL = Quality of Life
ES = Effect size
PRISMA = Preferred Reposting Items for Systematic Reviews and Meta-Analysis
OLS = ordinary least squares
GLM = generalized linear model
NLR = normal linear regression
RMSE = root mean square error
MAE = mean absolute error
EEE = extended estimating equations
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2SLS = 2-stage least squares
FIMSL = full information maximum simulated likelihood
LATE = local average treatment effect
ATET = average treatment effect on the treated
GAMLSS = generalized additive models for location scale and shape
MAPE = mean absolute predication error
MSE = mean square error
FE = fixed effects
CVD = cardiovascular disease
SD = standard deviations
MUSC = Medical University of South Carolina
MD = medical doctor or physician
NP = nurse practitioner
TH = Telehealth
PRO = patient-reported outcomes
DRG = Diagnosis-Related Group

CHAPTER 2
LITERATURE REVIEW

The literature review will not be an extensive review as this project is
demonstrating the limited research and gaps in the literature regarding the approach to
cost analysis.
2.1. Multivariable methods in cost analysis
Cost and cost savings are becoming increasingly important for the US healthcare
system. During the first 5 months of 2019, over one hundred papers with a key word of
“cost savings” were published in major US journals; 7 in JAMA, 19 in PLoS ONE, and the
balance in other journals aimed at decision makers. This overwhelming focus on cost
savings makes it imperative that we begin to standardize our approach to cost analysis,
because different approaches have different underlying statistical assumptions and often
result in different outcomes.
Appropriate health care cost estimation is crucial as it is used to guide evidencebased health policy implementation. Health policy makers rely on costs to drive their
decisions (Power & Eisenberg, 1998). The estimation for costs associated with a disease,
such as diabetes, can influence the allocation of resources for the prevention and
treatment of the disease (Fukuda, Ikeda, Shiroiwa, & Fukuda, 2016). As numerous
administrative data sources have become available for analysis, it is essential that these
data are analyzed properly. These claims data, or billing data, are usually observational
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data sources, such as Medicare billing data, that are often assessed for health
care cost outcomes. Inaccurate cost analysis can lead policy makers to make sub-optimal
decisions.
Analysis of large datasets of observational data come with its own challenges.
Data are often skewed and group comparisons often biased. Cost data are commonly
positively skewed with a few outlying patients, often those with complications or who are
very ill, disproportionately consisting of much of the total costs (Dodd, Bassi, Bodger, &
Williamson, 2006; Bohl, Blough, Fishman, Harris, & Phelan, 2013; Malehi, Pourmotahari,
& Angali, 2015; Kurz, 2017). Administrative data can often include zero costs or zero
observations (non-users) that may make up a large proportion of the data (Malehi,
Pourmotahari, & Angali, 2015; Kurz, 2017). Further challenges arise when analysis of cost
data also need to consider censored data within the research time frame (Dodd, Bassi,
Bodger, & Williamson, 2006). Healthcare cost can vary according to region, health care
system, population, and payer; thus, adjustment of costs is needed for comparisons
across these factors. There are many different methods currently being used to estimate
costs including: generalized linear models with a log link, natural logarithm transformed
costs, gamma distribution, median regression, two-part models, and Bayesian models. As
cost drives many health care policies, inaccurate analyses of cost can have serious
consequences.
A review of approaches that compare cost analysis methods, which are conducted
statistically and mathematically, is essential to provide needed evidence as to which
methods are the most appropriate and valid for the evaluation of claims data. Therefore,
we conducted such a systematic review to identify what methods of cost analysis are
statistically and mathematically appropriate to use with large claims data and, specifically,
determine whether one method could be considered optimal. The knowledge gained from
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this review can be used to guide evidence-based cost analysis and properly assist policy
makers’ decisions.
The systematic review aimed to identify what methods of cost analysis are
statistically and mathematically appropriate to use with large claims data. While most
papers used established methods, there were three papers that introduced new methods.
The most commonly assessed models were OLS and Gamma distribution models. The
GLM Gamma distribution with Log link performed most consistently as the superior model
in comparisons using both simulated data and real administrative data. The literature
review suggests that this is the most appropriate model to use with administrative data.
Some caution is suggested when dealing with heteroscedastic data or data with high
proportion of zero costs (or non-users). The Tweedie distribution is an emerging new
method that may be useful in future research (Kurz C. , 2017).
2.2. Minimally Important Difference
Minimal clinically important difference (MCID) was developed by Jaeschke, Singer,
Guyatt (Jaeschke, Singer, & Guyatt, 1989) to create interpretability of change in score of
Quality of Life (QOL) Questionnaires in “most influential paper in MID history” (King, 2011).
Jaeschke et al. defined MCID, or as later referred to as minimally important difference
(MID), as the “the smallest difference in score in the domain of interest which patients
perceive as beneficial and which would mandate, in the absence of troublesome side
effects and excessive cost, a change in the patient’s management” (Jaeschke, Singer, &
Guyatt, 1989). There are three methods to determine MCID: anchor-based, distributionbased, and consensus-based.
The anchor-based method assesses the relationship between the change in score
of the inconclusive questionnaire (target) with an independent measure (anchor) with an
already known interpretation and association with the target (Gyatt, et al., 2002). These
anchors are either individual based, a single anchor that uses within-patient or between-
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patients anchors for interpretation, or population based, a multiple anchor that uses
population based clinical measures for interpretations. For the latter, the change scores in
the target QOL are compared to the proportion of people experiencing a clinical measure
(e.g. health utilization, suicidal ideation, walking a block, job loss, mortality) (Gyatt, et al.,
2002). Unfortunately, the multiple anchor approach does not have a lot of information yet,
and no examples of specific studies were discussed.
The single anchor seeks to quantify the changes in QOL into trivial, small,
moderate, or large categories. There are two methods used to determine these categories:
with-in patient and between-patient. The within-patient method uses a patient’s own
reported change from their perspective as reference. The target QOL questionnaire is
given at each timepoint, including baseline, and a global rating questionnaire additionally
completed at all subsequent visits (not baseline). The global rating questionnaire asks the
patient to rate if their “condition” has improved (e.g. no change, better, or worse) from their
perspective since the last visit. Any change is then quantified by the patient on a 7-point
Likert scale (e.g. 1. Almost the same, 2. A little worse/better, 3. Somewhat worse/better,
4. Moderately worse/better, 5. A good deal worse/better, 6. A great deal worse/better, 7.
A very great deal worse/better) and degrees commonly established as: 1-3 considered
small changes (MID), 4-5 moderate changes, and 6-7 large changes. The MID range can
then be determined by comparing the change in QOL target score for each of the degrees
(i.e. small, moderate, and large) and using ROC curves to minimize the misclassifications
for optimal cut-points (Gyatt, et al., 2002). The between-patient method is similar to the
with-in patient method. A global ratings questionnaire is completed the target
questionnaire at all subsequent visits. However, instead of comparing their status to their
previous status, patients pair off to discuss their statuses and then rate their status
compared with their partnered pairs’ status (same, worse, better). The MID range is
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determined by the difference in QOL score in patients that rate themselves “little better”
or “little worse.”
There are several limitations to the single anchor method. The same absolute
difference in score may have different meaning across different portions of the scale (e.g.
20 to 30 mean something different than 90 to 100) and Gyatt believes the proportion of
patients achieving benefit is more important than mean difference (Gyatt, et al., 2002).
There is also the potential for recall bias, for example, the prospective of change is
correlated with present condition (King, 2011; McGlothlin & R, 2014) and the sample size
in each degree of global rating change group may be small (King, 2011).
The distribution-based method of determining MID examines the relationship
between the magnitude of effect and variability (Gyatt, et al., 2002). Typically, this is
expressed as a ratio called Cohen’s D, where the magnitude is within patient difference
and variability is between patient variability for the control group (baseline) or the pooled
variability of control and treatment groups (baseline) (Gyatt, et al., 2002; King, 2011).
There are 2 inherent limitations to this method to be considered. First, that variability is
different for each study, thus, effect sizes may not be comparable across different
populations with varying degrees of homogeneity (Gyatt, et al., 2002). The second
limitation is the interpretability of effect size in terms of standard deviation is not easily
understood and applicable to practicing clinicians. Cohen sought to address the latter
limitation by suggesting ranges of 0.2. 0.5, and 0.8 as small, moderate, and large changes,
respectively. There has been some concern as to the arbitrariness of these cut points;
however, studies have provided evidence that suggest the plausibility of Cohen’s ranges
and consistency of standard deviations and MID within a same instrument.
The final method, consensus (Delphi), was developed by the Rand Corporation
around 1950. Expert judgement is often needed to solve complex problems when a
definitive conclusion is not available. The Delphi uses expert opinion in a series of rounds
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(King, 2011). Its first significant use was in 1953, by Dalkey and Helmer, to assess 7
experts’ judgement of atomic warfare (Pill, 1971; de Villiers, de Villiers, & Kent, 2005; Okoli
& Pawlowski, 2004). The objective of the method is to gain the judgement of a panel of
selected experts in a field (Okoli & Pawlowski, 2004). The Delphi method is conducted
anonymously using questionnaires sent by mail, e-mail, or fax; this anonymity reduces
bias that may occur from dominant personalities within a group of experts (Okoli &
Pawlowski, 2004). Each question provides an opportunity to provide feedback to explain
choices while providing opportunities to for individuals to reevaluate their stance given
information provided by other experts (Okoli & Pawlowski, 2004).
The Delphi method requires identifying and recruiting qualified experts; however,
the method of eliciting responses by paper provides the opportunity to build a panel of
experts from various geographical regions. The first questionnaire may be developed from
a literature review conducted by the research team or created with open-ended questions
with the intent to obtain expert opinion (de Villiers, de Villiers, & Kent, 2005). Any
structured items are developed for the questionnaire using one of two methods to
formulate the responses: ranking or rating. The ranking method requires the researchers
to devise a ranking system for the experts to utilize, whereas, the rating system uses level
of agreement from finite Likert scales (de Villiers, de Villiers, & Kent, 2005). Ranking
system asks participant to rank a group of factors in order of priority. Likert scales are
recommended to not include a neutral option to prevent participants from not providing a
definitive rate, such as a 4-point Likert using strongly agree, agree, disagree, and strongly
disagree (de Villiers, de Villiers, & Kent, 2005).
The first round of questionnaires sent out to the experts with structured items for
ranking/rating as well as a comment explaining the decision for the individual expert’s
response (de Villiers, de Villiers, & Kent, 2005). Finally, experts are asked to provide
overall feedback and questionnaires sent back to the researchers. The second round of

15
questionnaires is formulated by the analysis of the first round, with a summary sent back
to each expert containing each item not meeting consensus including their original
response as well as a summary of the other experts’ responses. The review of opposing
and similar opinions gives each participant a chance to reevaluate their response.
To analyze the items on the questionnaire requires various methods. The
assessment of rankings is best analyzed using Kendall’s W coefficient of concordance
(Okoli & Pawlowski, 2004). Coefficients of 0.7 or higher correlates to a strong agreement
and consensus is achieved, however, coefficients less than 0.7 require reevaluation by
the experts (Okoli & Pawlowski, 2004). This is continued at each round until either the
coefficient reaches 0.7, the maximum number of promised rounds are reached, or there
are no significant change in rankings of successive rounds indicating a lack of movement
toward consensus (Okoli & Pawlowski, 2004). For the assessment of ratings mean scores
that fall in the middle, e.g. around 2.5 on a 4-point Likert scale, correspond to nonconsensus (de Villiers, de Villiers, & Kent, 2005). Consensus is considered reached if
rating score ceases to change significantly between rounds. The main limitation of this
method is the lack of patient perspective.
2.3. Effect size in healthcare
Potential papers were identified by searching the database Scopus using the
following search terms: “effect size” and “healthcare” in the title, abstract, or keywords.
Searches were conducted for all articles published up to the end of January 2019.
Only papers reporting effect sizes were included, excluding those that define effect
sizes as ratios (e.g. odds ratio, hazard ratio, incident rate ratios), correlations, or
regression coefficients. Additional exclusions included papers not being published in
English, method papers, book chapters, review papers, and those reporting effect size but
giving no interpretation of the effect size. Data elements extracted from eligible papers
include: paper’s first author, year of publication, outcome(s) being measured by effect size,
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effect size method(s) used, interpretation of effect size values or ranges, and citations
used for effect size methods and/or interpretation. The titles and abstracts of all papers
found utilizing the search terms in the database were reviewed for potential eligibility.
Among those titles and abstracts meeting potential eligibility, the full text article was
reviewed for eligibility to be included in the literature review.
The search of the database identified 698 potential papers, after title and abstract
review there were 340 papers that met initial inclusion criteria for full article review (Figure
1). There were 184 papers that were included in the review and summary data extracted
(Table 1). There were about 30 different, although many similar, definitions of effect size
(ES) reported across the 184 papers. The most common type of ES calculation used was
Cohen’s d (49.7%), another 24 (13%) of papers provided the formula for ES used that was
similar to Cohen’s d, and about 10% did not define the type or provide a formula of ES
they used. The interpretation of ES by ranges or cut points were not provide by some
papers, offering only the interpretation of specific ES found, however, many papers did
provide the ES ranges and cut points for interpretation. The most common cut points for
the interpretation of small, medium/moderate, and large ES were 0.02 (43.2%), 0.5
(38.8%), and 0.8 (43.7%), respectively.
References regarding ES calculation and ES interpretation were examined across
all the included papers with almost half (42.4%) not including a citation in the paper. Cohen
was most frequently referenced author (41.9%; 72.6% of papers with references to ES)
with over a third of the papers (34.8%) referencing Cohen’s book “Statistical Power
Analysis for Behavioral Sciences.”
2.4. Develop an efficient tool for measuring costs for the calculation of value of care
Hospitals commonly use mean values based on data from their own accounting
system when estimating the cost of care for decision making processes as this is the least
resource intensive approach. The hospital accounting cost are often based on the internal
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cost from accounting data with a “stepdown” allocation of indirect costs, where
departments are ordered in a hierarchical fashion and all indirect costs are distributed
step-wise to the departments below until only one department is left. The hospital
accounting system depends on the institution’s historical production flows and may be
skewed by factors associated with overhead allocations aiming at maximizing
reimbursement and collection rates that best maximize profits. Thus, a hospital’s internal
accounting system is skewed towards resource use patterns associated with the average
patient and are often not representative of true cost (Zilberberg & Shorr, 2010; Carroll &
Lord, 2016).
The true cost of a care process usually requires a micro-costing approach to
measure. Micro costing establishes patient specific resource use directly attributed to
actual diagnostics, devices, and drugs used in treatment and patient specific treatment
times to determine actual labor resources use (Tan, Rutten, van Ineveld, Redekop, &
Roijen, 2009; Carroll & Lord, 2016). This more detailed level of costing provides the ability
to identify subpopulations (e.g. race, comorbidity, age group) most affected by costs (Tan,
Rutten, van Ineveld, Redekop, & Roijen, 2009). Time-driven activity-based costing
(TDABC) is a micro-costing methodology that identifies each specific activity and resource
use with indirect costs estimated using hospital defined estimates for the specific
resources used to determine true costs (Gammon & Cotten, 2016; Carroll & Lord, 2016).
TDABC uses a management engineering approach of direct observation of the process
and the collection of a large sample of relevant data by stopwatch and observation of the
care process. Typically, TDABC is conducted with research staff present in the clinical
setting during all operational hours to be immediately available when patients arrive for
treatment, tracing and documenting the specific activities related to the treatment manually
by use of a stopwatch. Each research staff can only trace one patient at a time, therefore,
in the event that more than one patient is going through the process during overlapping
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times, opportunity to collect data on the additional patients is lost. Furthermore, data needs
to be collected on approximately 40-50 patients to have obtained a sample large enough
to satisfy the statistical “law of large numbers” (more than 30 viable observations) needed
to evaluate costs.
Literature suggests that TDABC is an effective method to find true costs which can
be used to identify inefficiencies and cost drivers within processes. In one study,
researchers demonstrated how this precise method of costing was used to address a
concern that health care administrators were emphasizing blood transfusions over other
alternatives based on a misconception of actual cost, affecting quality of care. The
researchers determined the true costs of blood transfusions, using activity-based costing
to include the costs of acquiring and administrating, were much more costly than the mean
acquisition costs used by administrators to inform clinical process decisions (Shander, et
al., 2010). At Boston Children’s Hospital, TDABC and process mapping identified an area
to improve efficiency by the addition of a physician assistant (PA) that decreased patient
waiting times and increased revenue (Kaplan & Witkowski, 2014). Similar results were
found when a psychiatrist in Norway used the process to analyze the efficiency of his clinic
and discovered a need to modify the care process; resulting in better outcomes and
improved capacity (Kaplan & Witkowski, 2014). Another study in a preoperative
assessment center applied TDABC methods to evaluate the two-phase implementation of
a process improvement initiative that ultimately reduced process time by 33% and cut cost
of care by almost half, without negatively impacting outcomes (French, et al., 2013). These
examples are indicative of the potential for process improvement and cost savings.
Nonetheless, since this method for determining cost is very resource intensive, it is rarely
employed for hospital cost estimation. The biggest barrier to implementing TDABC is that
it is resource intensive; requiring research staff present in the clinic to observe and record
the care processes of each patient using a stop watch to manually collect the timing of
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processes and resource use. Consequently, it is not known how much the method used
for costing affect the calculation of value.
A solution to this shortcoming could be through use of structured interviews and
electronic health records (EHR), providing a more efficient approach to record times of the
sequence of events via electronic time stamps to implement TDABC. EHR activity logs
have been effectively utilized to evaluate quality and efficiency of workflow and process of
care (Mans, et al., 2008; Chen, et al., 2015; Wu, et al., 2017).
2.5. Electronic Health Records and Value Measurement
The Panel of Cost-Effectiveness in Health and Medicine, a group organized to
develop standardization in cost-effective analyses, recommends micro costing methods
for studies conducted within organizations (Weinstein, Siegel, Gold, Kamlet, & Russell,
1996). Unfortunately, micro costing is both costly and time-consuming and, despite its
greater accuracy, this is the main barrier to its implementation (Tan, Rutten, van Ineveld,
Redekop, & Roijen, 2009; Carroll & Lord, 2016). Every time a hospital care process is
changed in a major way, decision makers must decide if the additional costs of micro
costing, with its high resource use and slow time line, is justified by its more accurate cost
data (Tan, Rutten, van Ineveld, Redekop, & Roijen, 2009). Thus, a faster, less resourceintensive costing method would greatly benefit hospital managements’ ability to identify
good value for money invested in process improvements. A potential solution may be
found in the electronic health record (EHR)
Health care systems have increasingly focused on the secondary use of EHR for
data to evaluate quality and efficiency of workflow processes as a cost-effective
alternative. This secondary application was demonstrated in a pilot study that successfully
used EHR time logs to model workflows that evaluate efficiency and determine areas for
process improvement (Chen, et al., 2015). Wu et al. evaluated the feasibility and validity
of EHR timestamps use in the assessment of workflows and determined the timestamps
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were a feasible and valid source of accurate data for identifying health care processes
and reduced behavioral bias associated with being observed (Wu, et al., 2017). EHR time
logs have been used to assess efficiency in workflow models and identify areas for
process improvement, as well as, evaluate quality of care processes and determine when
care deviates from usual process of care (Zhang, Mehotra, Liebovitz, Gunter, & Malin,
2013; Karp, Freeman, Simpson, & Simpson, 2018; Chen, et al., 2015). The use of
computerized time stamps from EHR to validate the times of a sequence of events in the
process of care has the potential for being a cost saving and accurate costing method.
This approach is promising in that it significantly reduces the resource cost associated
with research staffing needed to observe and record time segments in the process using
a stopwatch.
2.6. Examples of studies that use less than optimal approaches to report on cost data
Cost data comes with its own challenges that often include non-negative values, large
of number of zero costs (non-users of healthcare utilization), right skewed from a few
outlying patients that disproportionately consist of much of the total costs, and
heteroscedasticity (non-constant variance). Popular models in the literature to analyze
these cost data are ordinary least squares (OLS) linear regression, with and without log
transformation, and generalize linear models (GLM) with gamma distribution and log link,
however, many studies comparing the two methods have found GLM gamma with log link
to have superior performance over OLS regressions.
In 2003, Mandell et al. analyzed the service use and costs of psychiatric disorders
using ordinary least squares (OLS) linear regression with no log transformation based on
the robustness of large sample size (Mandell, Guevara, Rostain, & Hadley, 2003). While
some state that as sample sizes get larger, the robustness of OLS with a log
transformation improves similarly to GLM Gamma with Log link, however, it is not
considered to be robust for heteroscedasticity and the authors did not use log
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transformation (Malehi, Pourmotahari, & Angali, 2015). OLS without log transformation
requires meeting assumptions of normality including homoscedasticity. Ignoring the
violations leads to biased estimates that may provide incorrect conclusions (Dodd, Bassi,
Bodger, & Williamson, 2006; Malehi, Pourmotahari, & Angali, 2015; Basu, Arondekar, &
Rathouz, 2006). The GLM Gamma with Log link has been found a consistently much better
model that provides more precise estimates than OLS and performs well with small bias
for both small and large sample sizes. The GLM gamma retains the original scale of the
data providing an accurate interpretation with the least amount of bias (Bohl, Blough,
Fishman, Harris, & Phelan, 2013; Dodd, Bassi, Bodger, & Williamson, 2006; Malehi,
Pourmotahari, & Angali, 2015; Manning & Mullahy, 2001).
Nichols et. al. analyzed the annual direct costs of follow-up medical utilization among
patients that entered a cardiovascular disease (CVD) registry (Nichols, Bell, Pedula, &
O'Keeffe-Rosetti, 2010). The authors stated they analyzed costs using Proc GLM with no
transformation (i.e. OLS) for “straightforward interpretation of the parameter estimates.”
The justification given for not transforming was they found “no change in direction or
statistical significance of the results” when cost were analyzed using a log transformation.
Finding a similar direction or statistical significance of costs in a known biased model by
comparing it against a more widely accepted method does not validate the erroneous
model’s cost estimates. OLS without transformation is shown to lead to bias estimates of
mean costs that may provide incorrect conclusions; these conclusions can affect decisions
based off those biased estimates (Dodd, Bassi, Bodger, & Williamson, 2006). The GLM
Gamma with Log link is the best-fit model for highly skewed data, regardless of sample
size, and provides accurate interpretation (Dodd, Bassi, Bodger, & Williamson, 2006; Bohl,
Blough, Fishman, Harris, & Phelan, 2013; Malehi, Pourmotahari, & Angali, 2015).
Wang et al. examined hospitalization costs for stroke patients using regression
analysis without log transformations (Wang, et al., 2014). The authors did not log
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transform data based on the exclusion of 1% trim of the top and bottom of data to avoid
outliers, large sample size, and the reference of 2 other published studies (discussed
above) siting no transformation for ease of interpretation. The authors attempted to control
the potential of outliers dominating model estimates and biasing results from
heteroscedasticity of variance by excluding them instead of using a model that could
handle these challenges. Large sample sizes may improve estimates in OLS models,
though a threshold for size has not been determined to identify when it would no longer
provide biased estimates (Dudley, et al., 1993). Studies comparing statistical modeling
methods show that OLS with no transformation is prone to overestimate estimates which
may impact decisions made from inaccurate estimates and conclusions.
In a more recent publication, Willink et al. published a cost-benefit analysis of hearing
care services in 2019, using OLS (no transformation mentioned) to analyze total spending
and spending by service type (Willink, Reed, & Lin, 2019). No rationale was given by the
authors for not transforming the data or addressing violation of assumptions.
The GLM Gamma distribution with Log link has been found to be the most appropriate
model for skewed data and/or heteroscedasticity, overall performed superiorly to OLS in
simulated studies and real observational data with accurate estimates, and retains the
data’s original scale for accurate interpretations. Inaccurate and biased estimates can lead
to incorrect conclusions that may impact decisions that affect the resource allocation in
healthcare (Dudley, et al., 1993; Dodd, Bassi, Bodger, & Williamson, 2006; Basu,
Arondekar, & Rathouz, 2006; Malehi, Pourmotahari, & Angali, 2015). OLS may perform
well in data without heavy tails or if sample sized are large enough, the unbiased estimates
are not consistent across studies. Furthermore, normal linear regression with
heteroscedasticity may lead to negative prediction of cost (Dodd, Bassi, Bodger, &
Williamson, 2006). While GLM Gamma distribution with Log link in not universally correct
for all data, it has been shown in multiple model comparison studies to perform as well as
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specialized models that fit specified data, allow for heteroscedasticity that is often found
in cost data, be a good fit for highly skewed data, overall be most reliable regardless of
sample size, and allow for the accurate interpretation of data on the original scale.

CHAPTER 3
METHODS

3.1. RESEARCH QUESTION 1
What methods of cost analysis are statistically and mathematically appropriate to use with
large claims data and is there one method that could be considered optimal?
3.1.1 Study Design
A systematic review identified what methods of cost analysis are statistically and
mathematically appropriate to use with large claims data. Only statistical method papers
using multivariable modelling of cost, with or without methods controlling for selection bias,
were included given they met one of the following inclusion criteria: 1) a comparison of
two or more statistical methods to analyze cost or 2) one statistical method performed on
two or more different types of cost data.
3.1.2 Data Collection
Data elements extracted from eligible papers included: paper’s first author, year of
publication, statistical methods being evaluated, data types used in analysis, year(s) the
data was collected, simulation approach used, sample size of data, distribution of the data,
the results of the method performance and the author’s recommendations based on their
results.
3.2. RESEARCH QUESTION 2
Can existing methods to determine minimally important differences in health outcomes be
used to identify minimally important differences in costs?
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3.2.1 Study Design
The project reported the MIDs derived using each of the three methods for cost
data from a hospital admission cohort (high-costs) and a clinic visit cohort (low-cost).
3.2.2 Data Collection
The hospital admission cohort consists of patients identified as having an opioidrelated event treated in any hospital in a state over a 3-year period. The clinic visit cohort
consists of cost data from outpatient visits incurred over 12 months for HIV-infected
adolescents from 4 clinics in different states in the US. These data were de-identified
and are part of ongoing exploratory studies deemed non-human research by our IRB.
The data are governed by data use agreements and not available for other use.
3.2.3 Data Analysis
MIDs were calculated using three methods: 1) anchor-based, 2) distributionbased, and 3) consensus-based. The anchor-based MID was calculated based on the
relationship of clinic care costs with the 2017 Medicare medical fees for the median (50th
percentile) cost for complex clinical visits. The distribution method was calculated based
on Cohen’s cutoffs of 0.2, 0.5, and 0.8 standard deviations (SD) for small, medium, and
large effect size (ES), respectively. The consensus-based method was conducted by
professionals from various backgrounds in an academic institution that assess cost
evaluations through a questionnaire that was administered via email.
3.2.4 Limitations
MIDs are useful for planning studies using quality of life and clinical assessment
tools. However, we have found no publications establishing a MID for costs.
3.3. RESEARCH QUESTION 3
Will the pediatric sick visit weighted labor cost, estimated using a modified TDABC, for a
clinic visit before the COVID-19 pandemic show a difference in mean cost than a clinic
visit during the COVID-19 pandemic?
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Aim 1
Use structured provider interviews to identify the major variations in patient flow and
describe the care process and resource use using TDABC workflow diagrams with time
indicators for a moderate complexity visit for an established patient.
Aim 2
Compare providers' minute estimates to minutes estimated from EHR time stamps from
telehealth "dashboard" data, and from Clarity EHR data, and estimate the uncertainty in
minute values using distributional parameters derived from CMS CPT standards and
Monte-Carlo simulations for 100,000 visits to estimate uncertainty in labor cost estimates.
Aim 3
Aggregate flow chart estimates and uncertainty measures in a decision tree and calculate
visit labor costs for an in-person sick visit before COVID-19 to a sick visit during the
COVID-19 pandemic.
H1: Mean weighted labor cost before COVID - Mean weighted labor cost during
COVID is < the MID defined by the anchor method as a difference between mean
payment for adjacent CPT codes
3.3.1 Study Design
A mixed methods approach was used for data collection and analysis to perform
a modified TDABC of a sick visit. A sick visit was defined as a low complexity clinic visit
(CPT 99213), classified as a 15-minute face-to-face visit. Visits were described for children
between the ages of 5-9 years old. The TDABC steps included: 1) recorded structured
interviews with providers, 2) iterative workflow mapping, 3) EHR timestamps for time
validation, 4) standard cost weights for wages, 5) clinic CPT billing code mix for complexity
weights and 6) simulations to assess effects of uncertainty on cost differences.
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3.3.2 Sample
This study was conducted using a pediatric clinic associated with an academic
hospital in the southeastern United States. The Medical University of South Carolina
(MUSC) is one of only two federally recognized telehealth Centers of Excellence,
identifying it as having an established and successful telehealth program with high volume.
MUSC has been providing telehealth programs across the state of South Carolina since
2005, reaching 42 of the 46 counties. Secondary data was obtained from the EPIC
electronic health record system used by MUSC. The study met institution IRB definition of
quality improvement project and did not require approval.
3.3.3 Data Collection
Structured interviews were used to collect data to map the care process of a sick
clinic visit for an established patient age 5-9. An interview guide with five questions with
probes was used (Appendix A). Interviews were conducted by two interviewers familiar
with the workflow and EHR system. Two providers were interviewed separately: a
physician (MD) and a nurse practitioner (NP). Both interviewers were present for both
sessions and the interviews were recorded.
Two independent sources of data from the clinic were used to extract visit time
stamps for clinic visits with CPT 99213. One set of process validation data was extracted
from the EPIC telehealth dashboard, used by practice managers and telehealth
personnel to monitor the processes in the clinic. Data were extracted for all clinic
pediatric patients seen during September 2020 with a low complexity clinic visit (CPT
99213). These data included the timestamps for check-in, treatment start time, provider
treatment team composition (i.e. MD or NP), record access by each actor, and printing
timestamp used by providers to present a visit summary and care plan for patients at the
end of the visit. A second data set was extracted from the EPIC Clarity Warehouse,
which included all CPT 99213 clinic visits in September 2019 and September 2020.
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To determine labor costs of each actor, median US salaries for each of the actor
were established using the US Bureau of Labor Statistics salary data for 2019. Monte
Carlo simulations were developed to mimic the variation of labor minutes by the
providers and staff, thus the variation of total labor cost, in the clinic setting. The
variation in minutes and cost per minute for actors provided a distribution of costs across
100,000 visits for in-person visits before COVID and telehealth and in-person visits
during COVID.
3.3.4 Data Analysis
3.3.4.1. Aim 1
The recorded interviews were processed using Rapid Qualitative Analysis to
develop the workflow charts. Iterative review of recording was used to reach agreement
on clinic flow between interviewers. The resulting flow charts were reviewed and edited
as needed by providers who then gave final approval of their position-relevant relevant
charts. The clinic mapping process for patients utilizing the clinic for a sick visit, from
signing-in at the beginning of the appointment to the conclusion of the clinic visit, began
with the review of the recorded interviews. Identification of each step in the process was
completed along with the determination of actors (e.g. MD, NP, nurse, front desk
personnel) and approximate time in minutes to complete each step. Three workflow charts
were then developed for 1) in-person clinic visits before COVID-19, 2) telehealth clinic
visits during COVID-19, and 3) in-person clinic visits during COVID-19. For each of the
workflow charts, steps of the process (identified by a square) are organized by the order
in which they are completed. Potential additional or alternative steps are identified with
decision nodes (diamond) in the flow chart. For each step of the process, the average time
to complete is noted (contained within small circle in bottom right corner of squares), and
actors involved (color-coded) are identified and listed. The three workflow charts were
created from each interview, then the interviews were reviewed again to make edits to the
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workflow charts. The two interviewers then met to review the workflow charts and both
interviewers agreed on the construction of the workflow chart.
The workflow chart was reviewed while listening to the recorded interviews and
check to be sure there were no missing connections and then returned to the interviewees
for verification of accuracy. Once any suggested edits were completed, the interviewers
reviewed the recorded interviews to ensure the accuracy of the workflow charts. This
process was repeated as analysis of minutes and cost were conducted. The workflow
charts generated by the MD and NP were combined to create a single clinic process
workflow chart for each visit type before and during COVID-19.
Using time-driven activity-based costing methods, the true labor cost of care was
assessed for in-person clinic visits before COVID-19 and the telehealth and in-person
clinic visits during COVID-19. To determine labor costs of each actor, median US salaries
for each of the actor were established using the US Bureau of Labor Statistics salary data
for 2019. Total loaded salary for each actor was evaluated as median salary plus fringe
benefits (e.g. health benefits, vacation package), the latter assessed at 35% of the median
salary. A total of 2,080 annual hours worked were assumed for a full-time employee; a
work capacity rate was assessed for nursing (e.g. Licensed Practical Nurse (LPN) and
Certified Medical Assistant (CMA)) and administration staff at 80% (1664 hours) and for
provider (e.g. MD and NP) at 72.3% (1504 hours). The cost per minute for each actor was
calculated as the total loaded salary divided by the number of capacity hours per year
divided by 60 (minutes). For process steps that were either completed by two different
actors or may potentially be completed by two different actors, as identified in the workflow
chart, a 50/50 weight was given to each actor’s salary to estimate the cost per minute for
the time in the mixed process step.
The cost of each actor for the visit is determined by the total minutes utilized
multiplied by the cost per minute for the actor. For in-person and TH sick visit, the labor
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costs across all actors are summed to determine the total labor cost of the clinic visit.
Analysis of labor cost was conducted using Microsoft Excel.
3.3.4.2. Aim 2
For Aim 2, providers' minute estimates from interviews were validated by the
minutes estimated from EHR time stamps from telehealth "dashboard" data, and from
Clarity EHR data. Mean (SD) in minute values were used to validate the minute estimates
in the clinic flow charts and to identify visits with CPT billing codes for tests and time
stamps for validating prescription-related process effects. These data were used to
estimate the mix of visits to generate complexity weights for the cost estimates. A second
data set was extracted from the EPIC Clarity Warehouse, which included all CPT 99213
clinic visits in September 2019 and September 2020. These data were used to validate
virtual visit time stamps and to estimate in-person visit time stamps to be used for
estimating visit costs.
Monte-Carlo simulations were developed to estimate the uncertainty in minute
values using distributional parameters derived from CMS CPT standards conducted with
100,000 simulated visits to estimate uncertainty in labor cost estimates. The provider time
was simulated using a Weibull distribution identified by Medicare specified range for the
visit type. All other staff time was modeled on a Beta PERT distribution defined by a
minimum and maximum value. Median salary for actors were also varied on a normal
distribution. The variation in minutes and cost per minute for actors provided a distribution
of costs across 100,000 visits for in-person visits before COVID and telehealth and inperson visits during COVID. Simulations were conducted using Crystal Ball software.
3.3.4.3. Aim 3
Aim 3 aggregated flow chart estimates and uncertainty measures in a decision tree
and calculated weighted sick visit labor costs for an in-person sick visit before COVID-19
to a weighted sick visit during the COVID-19 pandemic. EHR data extracted from EPIC
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Clarity warehouse was used to identify and categorize providers to determine a provider
mix for the same week in September for 2019 and 2020. Decision trees were constructed
using the identified provider mix and delivery method mix to calculate an average weighted
visit cost using the mean and +/- 1 standard deviation estimated from the labor cost Monte
Carlos simulations conducted in Aim 2.
Differences were evaluated between weighted mean of forecasted visit cost
estimated by simulations for before COVID and during COVID. Minimally important
difference (MID) measured by a well-defined anchor has been identified as a conservative
effect size for low-cost studies (Dooley, Simpson, Nietert, Williams Jr., & Simpson, 2021).
The anchor-based MID was based on the relationship of clinic care costs between the low
complexity sick visit (CPT 99213), defined as a 15-minute face-to-face clinic visit, and the
moderate complexity sick visit (CPT 99214), defined as a 25-minute face-to-face clinic
visit. The median Medicare medical fee in 2017 was $125 and $184, for low and moderate
complexity visits, respectively. The meaningful payment difference between the two visits
is $59 for 10 minutes.
3.3.5. Limitations
There is no direct benefit to patients analyzed for this study. The modified TDABC
method will eliminate the need for research staff to trace patients to determine a workflow
map in order to have the adequate sample size needed to conduct analyses. The results
will be relevant for informing essential discussions about: 1) which TH programs to keep;
2) how to improve TH efficiency; and 3) least costly mixes of TH and in-person visits.

CHAPTER 4
MANUSCRIPT 1
Systematic review of statistical methods for analyzing healthcare cost in
administrative data
4.1.0 Abstract
BACKGROUND: Healthcare costs are increasing at alarming rates in the United States
(US) putting a heavy burden on the healthcare reimbursement system. Cost and cost
savings have become an important focus as health policy administrators are tasked with
determining the most effective allocation of limited resources. The availability of large
databases, such as administrative data, comes with many challenges for analyses,
including: skewed data, inflated zero counts, and potential selection bias among
comparison groups. Thus, it is imperative that they are evaluated correctly. There are
many different methods currently being used to estimate costs including: generalized
linear models with a log link, natural logarithm transformed costs, gamma distribution,
median regression, two-part models, and Bayesian models. This systematic review will
identify which methods are statistically and mathematically appropriate for large claims
data.
METHODS: Scopus and Ovid were searched for potential statistical method papers using
multivariable modelling of cost that were published up to the end of February 2018.
Inclusion criteria required either a comparison of two or more statistical methods to
analyze cost or one statistical method performed on two or more different types of cost
data. This systematic review follows the guidelines according to Preferred Reposting Items
for Systematic Reviews and Meta-Analysis (PRISMA).
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RESULTS: The review identified 1,048 potential papers, of which, 80 met the inclusion
criteria for a full article review. There was a total of 9 papers included in the systematic
review; one paper included simulations and eight papers assessed real cost data. There
were 28 models assessed across the nine papers with ordinary least squares (OLS) and
generalized linear models (GLM) being the most common.
CONCLUSIONS: GLM using the gamma distribution was included in all but two of the
comparisons. Most other models that were compared to the GLM Gamma distribution with
log link found it to be the superior model in both simulated data and real administrative
data.
4.1.1. Background
Cost and cost savings are becoming increasingly important for the US healthcare
system. During the first 5 months of 2019, over one hundred papers with a key word of
“cost savings” were published in major US journals; 5 in the New England Journal of
Medicine, 4 in JAMA, 3 in PLoS ONE, and the balance in other journals aimed at decision
makers. This overwhelming focus on cost savings makes it imperative that we begin to
standardize our approach to cost analysis, because different approaches have different
underlying statistical assumptions and often result in different outcomes.
Appropriate health care cost estimation is crucial as it is used to guide evidencebased health policy implementation. Health policy makers rely on costs to drive their
decisions (Power & Eisenberg). The estimation for costs associated with a disease, such
as diabetes, can influence the allocation of resources for the prevention and treatment of
the disease (Fukuda, Ikeda, Shiroiwa, & Fukuda, 2016). As numerous administrative data
sources have become available for analysis, it is essential that these data are analyzed
properly. These claims data, or billing data, are usually observational data sources, such
as Medicare billing data, that are often assessed for health care cost outcomes. Inaccurate
cost analysis can lead policy makers to make sub-optimal decisions.
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Analysis of large datasets of observational data come with its own challenges.
Data are often skewed and group comparisons often biased. Cost data are commonly
positively skewed with a few outlying patients, often those with complications or who are
very ill, disproportionately consisting of much of the total costs (Dodd, Bassi, Bodger, &
Williamson, A comparison of multivariable regression models to analyse cost data, 2006;
Bohl, Blough, Fishman, Harris, & Phelan, Are generalized additive models for location,
scale, and shape an improvement on existing models for estimating skewed and
heteroskedastic cost data? , 2013; Malehi, Pourmotahari, & Angali, Statistical models for
the analysis of skewed healthcare cost data: a simulation study, 2015; Kurz C. , 2017).
Administrative data can often include zero costs or zero observations (non-users) that may
make up a large proportion of the data (Malehi, Pourmotahari, & Angali, Statistical models
for the analysis of skewed healthcare cost data: a simulation study, 2015; Kurz C. , 2017).
Further challenges arise when analysis of cost data also need to consider censored data
within the research time frame (Dodd, Bassi, Bodger, & Williamson, A comparison of
multivariable regression models to analyse cost data, 2006). Healthcare cost can vary
according to region, health care system, population, and payer; thus, adjustment of costs
is needed for comparisons across these factors. There are many different methods
currently being used to estimate costs including: generalized linear models with a log link,
natural logarithm transformed costs, gamma distribution, median regression, two-part
models, and Bayesian models. As cost drives many health care policies, inaccurate
analyses of cost can have serious consequences.
A review of approaches that compare cost analysis methods, which are conducted
statistically and mathematically, is essential to provide needed evidence as to which
methods are the most appropriate and valid for the evaluation of claims data. Therefore,
we conducted such a systematic review to identify what methods of cost analysis are
statistically and mathematically appropriate to use with large claims data and, specifically,
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determine whether one method could be considered optimal. The knowledge gained from
this review can be used to guide evidence-based cost analysis and properly assist policy
makers’ decisions.
4.1.2. Methods
Potential papers were identified by searching two databases, Scopus and Ovid,
using the following search terms: [“methodology" or "simulations" or "bootstrap" or
"bootstrapped" or "model comparison" or "compare models" or "markov" or “statistical
model” ] and [“cost data" or "claims data" or "billing data" or "health insurance data" or
"health insurance claims" or "billing claims" or "administrative data”] and [“cost analysis"
or "health care costs" or "hospital costs”] in the title, abstract, or keywords. Searches were
conducted for all articles published up to the end of February 2018.
Only statistical method papers using multivariable modelling of cost, with or without
methods controlling for selection bias, were considered eligible given they met one of the
following inclusion criteria: 1) a comparison of two or more statistical methods to analyze
cost or 2) one statistical method performed on two or more different types of cost data.
Since administrative cost data can be very different from cost data collected in a
randomized controlled trial, papers that used only data from randomized controlled trials
and not administrative data were excluded. Additional exclusions included not being
published in English and review papers. Bayesian methods and joint modelling methods
were considered beyond the scope of this review. Data elements extracted from eligible
papers include: paper’s first author, year of publication, statistical methods being
evaluated, data types used in analysis, year(s) the data was collected, simulation
approach used, sample size of data, distribution of the data, the results of the method
performance and the author’s recommendations based on their results.
The titles and abstracts of all papers found utilizing the search terms in both
databases were reviewed for potential eligibility. Among those titles and abstracts meeting

36
potential eligibility, the full text article was reviewed for eligibility to be included in the
systematic review. The reference lists of the included papers were also assessed to
identify additional eligible papers. A second reviewer verified the initial potential eligibility
of papers by reviewing 20% of the full list of the titles and abstracts originally obtained
from the search keywords in the Scopus database. This systematic review follows the
guidelines according to Preferred Reposting Items for Systematic Reviews and MetaAnalysis (PRISMA) (Liberati, et al., 2009). A meta-analysis was not assessed due to the
nature of the results of this review.
4.1.3. Results
The search of databases identified 1,048 potential papers, after title and abstract
review there were 80 papers that met initial inclusion criteria for full article review (Figure
4.1.6.1). There were nine papers that were included in the review and summary data
extracted (Table 4.1.6.1). A little more than half (55.5%) of these papers did not include
simulations to determine the best statistical methods for modelling cost. One paper only
looked at simulations and did not analyze statistical methods with real data. Of the eight
papers using real cost data, all but one (87.5%) indicated a positively skewed distribution
in their data.
4.1.3.1 MODELS
Of the nine papers, 28 models were assessed. The most commonly assessed
models were the ordinary least squares (OLS) and generalized linear model (GLM) using
the gamma distribution with log link; the latter used in comparison for all but two of the
papers reviewed. All other models were predominately assessed in one paper each. Thus,
comparisons of model performance between studies will be limited to OLS and GLM using
gamma distribution with log link. Details of the models and findings from each study are
provided below.
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Dodd et al. compared multivariable models of cost; normal linear regression (NLR)
of untransformed costs, NLR of log transformed costs (normal and Duan’s smear
retransformations), bootstrapped LR with robust standard errors, median regression, and
GLM using the gamma distribution with log link (Dodd, Bassi, Bodger, & Williamson, A
comparison of multivariable regression models to analyse cost data, 2006). Analysis was
evaluated on administrative data and model performance was compared using root mean
square error (RMSE) and mean absolute error (MAE). NLR and median regression had
the worst fit and predicted negative costs, indicating that these models do not fit skewed
data well. Log transformed NLR performed well on this data; however, it overestimated
mean costs. The GLM Gamma with Log link was the best fit model for the highly skewed
data.
Basu et al. evaluated OLS regression of untransformed costs, OLS log
transformed costs, GLM Gamma with log link, and extended estimating equations (EEE)
and compared goodness-of-fit using modified Hosmer-Lemeshow test, Pregibon’s link
test, and Pearson’s test (Basu, Arondekar, & Rathouz, Scale of interest versus scale of
estimation: Comparing alternative estimators for the incremental costs of a comorbidity,
2006). Assessment was conducted in administrative data of 7,428 patients that developed
heart failure. Tests showed that all OLS models and GLM Gamma were non-linear, thus,
the EEE model provided the best fit.
Garrido et al. compared 2-stage least squares (2SLS) of costs, 2SLS of log costs,
GLM Gamma regression with log link, and full information maximum simulated likelihood
(FIMSL) models (Garrido, Deb, Burgess, & Penrod, 2012). Model comparison was
evaluated by the local average treatment effect (LATE) and average treatment effect on
the treated (ATET). 2SLS models did not provide accurate estimates; however, the
authors recommend looking at GLM Gamma regression with log link and FIMSL models
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more closely as they both perform well in complex data and have similar estimates and
standard errors.
Bohl et al. evaluated OLS with log transformed models, GLM Gamma regression
with log links, and generalized additive models for location, scale, and shape (GAMLSS)
(Bohl, Blough, Fishman, Harris, & Phelan, Are generalized additive models for location,
scale, and shape an improvement on existing models for estimating skewed and
heteroskedastic cost data? , 2013). This was the earliest of the included papers to perform
simulations for model comparison along with assessment in real data. Simulations were
conducted using Gamma and generalized inverse Gaussian distributions. OLS had the
worst estimators, whereas the GLM model had the better performance overall. When the
models were evaluated using Medicare advantage data the GAMLSS model was not a
good fit. The GLM Gamma regression with log links performed the best.
Akbarzadeh et al. compared Poisson, negative binomial, zero-inflated Poisson,
and zero-inflated binomial regressions (Akbarzadeh, Pourhoseingholi, Zayeri, & Ashtari,
2013). Evaluation of models was conducted on survey data collected on a random sample
of 1,929 participants in Iran. Analysis verified assumptions that when data had large
variability such as unobserved heterogeneity or a large amount of zero costs, Poisson
regression was not appropriate. However, negative binomial models were better able to
handle unobserved heterogeneity. Lastly, in the case of a large number of zero costs, the
zero-inflated binomial performed best.
Kuwornu et al. assessed OLS models with: no cost transformation, a log cost
transformation with normal retransformation, heteroscedastic retransformation, and
Duan’s retransformation; robust regression, GLM models with: Poisson with log link,
Gamma with identity link, and Gamma with a log link (Kuwornu, et al., 2013). Models were
assessed by R2, mean absolute predication error (MAPE), and RMSE. Administrative data
was used to evaluate model performance. OLS log transformed costs with normal
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retransformation had the highest average R 2 reported, the robust regression had the
lowest average MAPE, and the OLS with no cost transformation had the lowest average
RMSE.
Malehi et al. compared OLS with log transformation models, GLM Weibull and
Gamma regression models with log links, and Cox proportional hazard models in
simulated data only (Malehi, Pourmotahari, & Angali, Statistical models for the analysis of
skewed healthcare cost data: a simulation study, 2015). Monte Carlo simulations were
conducted with varying levels of skewness using log-normal, Weibull, and Gamma
distributions with Gamma distribution having the least skewed data. The Cox proportional
model performed the worst across all distributions whereas the GLM Gamma was the
most superior overall. When data was highly skewed, the Weibull regression model
performed better than the Gamma model, though as sample size increased, the OLS
model precision approached that of the GLM Weibull and Gamma models.
Fiebig et al. used micro panels to compare OLS models to fixed effects (FE)
models. Models were evaluated by mean square error (MSE) and MAPE on the ability to
predict future costs and out-of-sample costs (Fiebig & Johar, 2017). Monte Carlo
simulations were conducted with varying correlations between the explanatory variable
and unobserved time-invariant effects. When there were no correlations between the
explanatory variable and unobserved time-invariant effects, the OLS model performed
better. However, when there were no time-invariant effects, the FE models were the best.
When there was a correlation between the explanatory variable and unobserved timeinvariant effects, FE models were better able to predict post-sample costs and OLS were
better able to predict out-of-sample costs. When the models were assessed in
administrative data with less than 3% of observations with zero cost, FE only performed
well in post-sample prediction while OLS was superior in out-of-sample predictions.
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Kurtz et al. compared the Tweedie distribution model to the Tobit, Poisson, and 2part models using the Gamma regression with log link and generalized Gamma regression
with log link (Kurz C. , 2017). They considered situations of both a high correlation between
group’s characteristics and a low correlation. Monte Carlo simulations were conducted
with varying proportions of zero costs. The simulations showed that when less than 20%
of observations had zero costs, the Tweedie model was the better fit when the correlation
between groups were high. However, for low correlations between groups the Tweedie
performed similarly to Gamma and generalized Gamma models when the proportion of
zero costs were low; however, the two-part models were better when simulations had
more than 20% of observations with zero cost. When the models were compared using
real administrative data with 18.1% of observations with zero cost, the Poisson and Tobit
models had a worse fit compared to the Tweedie and two-part models. As suggested by
the simulation data when zero costs were less than 20%, the Tweedie model had a similar
model fit as the 2-part models and may be considered an alternative approach in future
research.
4.1.4. Discussion
The systematic review aimed to identify what methods of cost analysis are
statistically and mathematically appropriate to use with large claims data. While most
papers used established methods, there were three papers that introduced new methods.
Kurtz et al. found their suggested Tweedie method could be an alternative approach to
analyze cost with a small number of zero costs, though, existing methods still performed
superior. Garrido et al. compared only novel models to each other, further research will be
needed to compare these to existing accepted methods.
The most commonly assessed models were OLS and Gamma distribution models. As
seen in Table 4.1.6.2, almost all the models that made comparison with the GLM Gamma
distribution with log link found this model to be the superior model. Kuwornu et al., who
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compared eight different models including OLS and Gamma distributions, stated that the
OLS Log model with normal retransformation had superior performance based on the
highest average R2 over 10-fold cross-validation; however, while the average R2 was
highest at 18.77, the values varied from 6.73 to 24.76 and were not consistent. Both the
GLM Gamma with identity and log links had consistent R 2 values over the 10 replications
with average values of 17.04 and 14.52, respectively. The same inconsistency in values
can be seen with the recommendations based on lowest RMSE values for the OLS model
of untransformed costs. Again, the Gamma with identity link performed just as well as the
OLS model. OLS model precision was found to approach that of the GLM Gamma models
as sample size increased in simulations conducted by Malehi et al.
4.1.4.1. Simulated vs. Real Data
All but one paper used real data to demonstrate the performance of their models.
While simulations are a useful tool to assess the accuracy of model performance, the use
of only simulated data can lead to biased results as simulations can be structured to fit a
particular statistical model for superior performance. Assessment of models in real data is
necessary to evaluate performance in uncontrolled environments. Some papers provided
incomplete rationales for decisions regarding data, such as excluding zero costs, which
may have biased the model assessment.
4.1.4.2. Limitations
To focus the scope of this review on the most common use of administrative cost
data, methods assessed in randomized controlled trial data only, those that evaluated the
effect of missing data, and those that assessed joint modeling methods were excluded.
This focus limited the evaluation of numerous methods in various data distributions and,
thus, limited the number of model comparisons.
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4.1.5. Conclusions
The GLM Gamma distribution with Log link performed most consistently as the
superior model in comparisons using both simulated data and real administrative data.
The literature review suggests that this is the most appropriate model to use with
administrative data. Some caution is suggested when dealing with heteroscedastic data
or data with high proportion of zero costs (or non-users). The Tweedie distribution is an
emerging new method that may be useful in future research.
4.1.6. Appendix – Tables and Figures
Figure 4.1.6.1. PRISMA flow chart.
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Table 4.1.6.1. Summary characteristics of methods, data, and results of reviewed papers.
Simulation
approach
used
None

Results of
simulation

Author’s
recommendation

None

GLM Gamma with
Log Link

Positive
skewed, no
zero cost

None

None

EEE

N=3389

Positive
skewed

None

None

GLM Gamma with
Log Link
Approach or
FIMSL

Not
Mentioned

N=2000

Positive
skewed, no
zero cost

Gamma
and
Generalized
inverse
gaussian

GLM
Gamma
with Log
Link

GLM Gamma with
Log Link

Survey

2006-2007

N=1929

Not
mentioned

None

None

Zero-inflated
Negative Binomial

Administrative
Data of
Saskatchewan,
Canada

1996-2010

N=17,480

Positive
skewed

None

None

OLS
OLS Log
transformed
(Normal
retransformation)

First Author

Year of
Publication

Methods being
evaluated

Data Types

Year(s)
data
collected
2000

Sample
size of
Data
N=426

Distribution
of Data

Dodd

2006

Hospital
Administrative
Data

Basu

2006

Garrido

2012

Bohl

2013

Akbarzadeh

2013

Kuwornu

2013

NLR
NLR Log
transformed
Bootstrapped NLR
Median regression
GLM Gamma with
Log link
OLS
OLS Log
Transformation (D
retransformation)
GLM Gamma with
Log Link
EEE
2-Stage Least
Squares
2-Stage Least
Squares Log
Transformed
GLM Gamma with
Log Link
Full Information
Maximum
Simulated
Likelihood (FIMSL)
OLS Log
transformed
(Normal
retransformation)
GLM Gamma with
Log link
GAMLSS
Poisson
Regression
Negative Binomial
Zero-inflated
Poisson
Zero-inflated
Negative Binomial
OLS
OLS Log
transformed
(Normal
retransformation)

Medstat’s
MarketScan

1997-2001

N=7428

Veteran’s
Health
Administration

2005-2006

Medicare
Advantage

Positive
skewed
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Malehi

2015

Fiebig

2017

OLS Log
transformed
(heteroscedastic
retransformation)
OLS Log
transformed
(Duan’s
retransformation)
Robust regression
GLM Poisson with
Log link
GLM Gamma with
Identity link
GLM Gamma with
Log link
OLS Log
transformed
(retransformation
not mentioned)
GLM Weibull with
Log link
GLM Gamma with
Log link
Cox Proportional
Hazard

OLS
Fixed Effects

Robust regression

None

None

None

None

Monte Carlo
simulated
with varying
levels of
skewness
using lognormal,
Gamma,
and Weibull
distributions
(no zeros)

Administrative
Data of New
South Wales

2006-09

N=264,02
4

Right skewed
< 3% zero
cost

Monte Carlo
simulated
with varying
correlation
between
explanatory
variable and
unobserved
timeinvariant
effects

GLM
models
performed
better.
Weibull
performed
better than
Gamma
with higher
skewness.
As sample
size
increased,
OLS model
precision
approached
GLM
precision.
Uncorrelate
d:
FEP is
superior
except
where there
are no
unobserved
timeinvariant
effects
Correlated:
FEP is
superior in
Postsample
forecast

GLM Gamma was
superior overall
Cox was superior
if Weibull
distribution

OLSP was
superior
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Kurtz

2017

Tweedie
Tobit
Poisson
2-part model:
Gamma with Log
link
Generalized
Gamma with Log
link

RAND HIE

Not
provided

N=3301

Right skewed
18.1% zero
cost

Monte Carlo
Simulated
with varying
proportions
of nonusers/zero
cost

OLSP is
superior in
out-ofsample
forecast
<20% zero
observation
s: Tweedie
>20% zero
observation
s: 2-part
models
Gamma
was better
than Gen
Gamma

Tweedie is an
alternative to the
superior 2-part
models

Table 4.1.6.2. Summary Models evaluated and preferred recommendations by author of reviewed paper (denoted as X*).
MODEL
NLR
Log NLR
Bootstrap NLR
OLS
OLS Log (Heteroscedastic)
OLS Log (Normal)
OLS Log (Duan)
GLM Gamma Log link
GLM Gamma Identity link
GLM Generalize Gamma
EEE
Median Regression
Robust Regression
2-Stage Least Squares
2-Stage Least Squares Log
FIMSL
GAMLSS
Poisson

Dodd
2006

Basu
2006

Garrido
2012

Bohl
2013

Akbarzadeh
2013

Kuwornu
2013

Malehi
2015

Fiebig
2017

Kurtz
2017

X
X
X
X
X

X*
X
X*
X
X
X

X
X*

X

X*

X*

X*

X*

X*
X*

X*
X
X*
X
X
X*
X
X

X
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Poisson Log Link
Zero-inflated Poisson
Negative Binomial
Zero-inflated Negative Binomial
Weibull Log
Cox Proportional Hazard
Tweedie
Tobit
Fixed Effects
Data Type

X
X
X
X
X
X
X
X
X
Real

Real

Real

Real/
Simulated

Real

Real

Simulated

Real/
Simulated

Real/
Simula
ted

MANUSCRIPT 2
Minimally Important Difference in Cost Savings: Is It Possible to Identify an MID
for Cost Savings?
4.2.0 Abstract
As healthcare costs continue to increase, studies assessing costs are becoming
increasingly common, but researchers planning for studies that measure costs differences
(savings) encounter a lack of literature or consensus among researchers on what
constitutes “small” or “large” cost savings for common measures of resource use.
Other fields of research have developed approaches to solve this type of problem.
Researchers measuring improvement in quality of life or clinical assessments have
defined minimally important differences which are then used to define magnitudes when
planning studies. Also, studies that measure cost effectiveness use benchmarks, such as
cost/QALY, but do not provide benchmarks for cost differences. In a review of the
literature, we found no publications identifying indicators of magnitude for costs. However,
the literature describes three approaches used to identify minimally important outcome
differences: 1) anchor-based, 2) distribution-based, and 3) a consensus-based Delphi
methods. In this exploratory study, we used these three approaches to derive minimally
important differences for two types of resource measures common in costing studies for:
1) hospital admissions (high cost); and 2) clinic visits (low cost).
We used data from two (unpublished) studies to implement the minimally important
difference (MID) estimation. Because the distributional characteristics of cost measures
may require substantial samples, we performed power analyses on all our estimates to
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illustrate the effect that the definitions of “small” and “large” costs may be expected to have
on power and sample size requirements for studies.
The anchor-based method, while logical and simple to implement, may be of limited value
in cases where it is difficult to identify appropriate anchors. We observed some
commonalities and differences for the distribution and consensus-based approaches,
which require further examination. We recommend that in cases where acceptable
anchors are not available, both the Delphi and the distribution-method of MID for costs be
explored for convergence.
4.2.1. Background
Concern about the growing spending trend in healthcare (Dieleman, Cao, A, & et
al, 2020) has prompted clinical and health policy decision makers to continually assess
benefits and value of new treatments and care processes with an objective to control costs
without sacrificing quality of care (Blumethal & Abrams, 2020; Baicker & Chandra, 2020).
Rising healthcare costs are a national problem, and as part of efforts to control costs,
studies to assess the effect of systems changes on costs abound (Hong, Nguyen, Yasay,
& et al, 2020; Farford, Pantin, Presutti, & Ball, 2019). However, few cost studies report a
formal power analysis, and the literature is silent on questions related to the magnitude of
cost. This may lead to inefficient study designs with excessive sample sizes. This happens
if we use a cost measure that does not provide the maximum power to detect a difference;
for example, using total cost over some time period, instead of disease specific cost, or if
we fail to consider known sub-group differences in expected cost as part of the
randomization or analysis plan. Furthermore, cost is a complex study variable, because it
may be viewed from an organizational finance or accounting perspective (fixed and
variable costs and budget impact) by some decision makers, or from an economic
perspective (opportunity cost or cost effectiveness) by other stake holders. Thus, it may
be important to specify an MID for cost in a study in such a way that has “face validity” as
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an MID of cost differences from both a financial management and an economics
perspective.
We found no studies indicating how to determine “big” or “small” cost savings, even
for common measures, such as hospital admissions or primary care visits. This absence
of a common understanding about the magnitude of meaningful cost savings is detrimental
to good planning for health care program evaluations, quality improvement assessments,
and for randomized studies that assess the value (cost and consequences) of innovative
health systems changes. If we do not know how big “Big” is, we may design studies that
are either under powered or inefficient, neither of which is desirable. Developing a
common understanding and language needed to discuss the concepts of magnitude
related to cost of care is needed, because health policy research relies on statistical
significance tests (p-values or confidence intervals) to judge the likelihood that cost
differences, associations, and effectiveness demonstrated in our policy studies are
unlikely to be due to chance. In this paper, we will 1) discuss the methods described in
the literature used to define MIDs, 2) use two common resource use categories (hospital
admissions and outpatient visits) that are important drivers of cost in many studies as
examples for applying MID approaches to cost data, 3) show how cost MIDs behave when
used in power analyses to inform study planning, and 4) make recommendations for
issues to be explored further as our understanding of the usefulness of MIDs for cost
improvement.
4.2.1.1. Literature of MIDs
The determination of a minimally acceptable difference for clinical measures can
be easily assessed through repeated use and clinician experience from observations of
the outcomes to identify what is clinically important. Other focus areas, such as quality of
life improvement, use guides to judge effect magnitude. The concept of a minimal clinically
important difference (MCID) was developed by Jaeschke, Singer, Guyatt to create
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interpretability of the change in score of Quality of Life (QOL) questionnaires (Jaeschke,
Singer, & Guyatt, 1989). A MCID, or as later referred to as minimally important difference
(MID), is defined as the smallest difference perceived as beneficial that would result in a
change of the patient’s management (Guyatt, et al., 2002). MIDs are identified by three
methods: 1) anchor-based, 2) distribution-based, and 3) consensus-based (Guyatt, et al.,
2002; King, 2011).
The anchor-based method maps the relationship between the change in score of
the inconclusive assessment (target) with an independent measure (anchor) that has an
already established meaningfulness and an association with the target (Guyatt, et al.,
2002). The anchor seeks to quantify the changes in score into trivial, small, moderate, or
large categories. However, one important point of this method is that it recognizes that
the same absolute difference in score may have different meaning across different
portions of the scale. As an example, a 10-point change from 20 to 30 is likely to mean
something different to patients and clinicians than a 10-point change from 90 to 100. Thus,
according to Guyatt, interpreting results in ways that consider the proportion of patients
achieving the incremental benefit may be more important than simply comparing mean
differences (Guyatt, et al., 2002).
The distribution-based method of determining MID examines the relationship
between the magnitude of effect and variability (Guyatt, et al., 2002). Typically, this is
expressed as a ratio called Cohen’s D, where the magnitude is within patient difference
and variability is between patient variability for the control group at baseline, or the pooled
variability of control and treatment groups at baseline (Guyatt, et al., 2002; King, 2011).
There are two inherent limitations to this method to be considered. First, variability of a
measure is different for each study, thus, effect sizes may not be comparable across
different populations with varying levels of homogeneity (Guyatt, et al., 2002). Second, the
interpretability of an effect size, in terms of a fraction of a standard deviation, may not be
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easily understood by many practicing clinicians and may therefore lack face validity for
clinical relevance. Cohen sought to address the latter limitation by suggesting that
commonly observed study differences encompass ranges of 0.2 SD, 0.5 SD, and 0.8 SD
for effects considered small, moderate, and large changes, respectively. There has been
some discussion in the literature about the arbitrariness of these cut points. However,
studies have provided evidence that suggest the plausibility of Cohen’s ranges and
consistency of standard deviations and MID within the same instrument.
The final method for specifying a MID involves a consensus or Delphi approach
using expert opinion. This approach was pioneered by the Rand Corporation in the 1950s,
where researchers recognized that expert judgement is often needed to solve complex
problems when a definitive conclusion is not obvious (Pill, 1971; Okoli & Pawlowski, 2004;
de Villiers, de Villiers, & Kent, 2005). The Delphi approach uses expert opinion refined
through a series of rounds (King, 2011). The objective of the method is to distill the
judgement of a panel of selected experts in a field using a process that is minimally
susceptible to bias from the experts’ personal characteristics, such as persuasiveness,
perceived status and charisma (Okoli & Pawlowski, 2004). The Delphi method is
conducted anonymously using questionnaires sent by mail, e-mail, or fax. Responses are
summarized and returned to the experts for re-evaluation, until consensus is reached, or
until it becomes clear that experts truly differ on this issue. Expert panel reconsiderations
under conditions of anonymity reduces bias that may occur in face-to-face discussions
where dominant personalities within a group of experts may sway the group’s expressed
opinion (Okoli & Pawlowski, 2004). The anonymity used in the Delphi method reduces
bias from dominant experts while capitalizing on their knowledge and insights through
repeated rounds with new responses based on summaries. The iteration provides an
opportunity for group members to provide feedback and explain their choices and for
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individuals to reevaluate their choice when given information provided by other experts
(Okoli & Pawlowski, 2004).
The use of MIDs for studies of patient-reported outcomes (PROs) has matured
(Revicki, Hayes, Cella, & J, 2008). It is recommended that MIDs be based on responses
and anchors that are correlated at >.30.
4.2.1.2. Application of MIDs to Cost Data
It is expected that MIDs may vary by context, and that a single MID may not be
sufficient for all study applications. Further, it is recommended that a MID should be based
on multiple approaches and triangulation of methods. It is also reported that different
methods for estimating MIDs often converge, and that a Delphi process is employed to
select MIDs that are relevant to a study (Revicki, Hayes, Cella, & J, 2008).
While any of the three approaches for the development of MIDs are accepted as
being appropriate for informing the planning of studies using QOL and clinical assessment
tools, it is not known whether these approaches could be translated into use for healthcare
utilization and costs. To examine how MIDs behave for cost studies, we chose to use cost
differences for hospital admissions and clinic visits as examples of high-cost and low-cost
study outcomes. These costs were chosen because these two types of units are often the
relevant resources on which interventions to reduce cost of care are focused. We used
(unpublished) data from studies of actual patient cohorts and their recorded cost measures
to specify MIDs and then used these MID specifications to examine the statistical power
and sample size variability imposed by each MID definition.
We examined the literature of MIDs for PRO studies to identify relevant criteria for
judging how our MIDs perform. Criteria discussions often stressed measurement validity
markers (construct validity, responsiveness) that are not central issues for cost studies.
Ideally a MID for cost would be: 1) constant across similar types of cost “drivers”; 2)
relevant for a specific costing perspective, and 3) be stable over a reasonable cost horizon.
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However, the assessment of MIDs on these criteria is outside the scope of this study. So,
instead of judging our MIDs against specific criteria, we used the convergent approach
recommended by Revicki and colleagues (2008) combined with a pragmatic comparison
on power and sample size. The literature of MIDs for PROs recommends the use criteria
for choosing MIDs that: 1) are based on selection of relevant ranges that emerge when
results are presented graphically; 2) weigh anchor-based results heavier that results from
other methods; 3) seek convergence between methods; and 4) use a modified Delphi
approach for development of consensus. The choice of describing MIDs as they behave
with regard to statistical power and sample size was pragmatic based on relevance to the
planning of cost studies of relevance to population health, health systems reengineering
and quality improvement efforts. This focus is supported by the statement Revicki and
colleagues (2008) for the use of MIDs for PRO research, that “MIDs are clearly useful for
calculating statistical power and for determining sample sizes for clinical trials”.
4.2.2. Methods
The hospital admission cohort consists of patients identified as having an opioidrelated event treated in any hospital in a state over a 3-year period. The clinic visit cohort
consists of cost data from outpatient visits incurred over 12 months for HIV-infected
adolescents from 4 clinics in different states in the US. These data were de-identified and
are part of ongoing exploratory studies deemed non-human research by our IRB. The data
are governed by data use agreements and not available for other use.
4.2.2.1. Anchor-based
The anchor-based MID was calculated based on the relationship of clinic care
costs with the 2017 Medicare medical fees for the median (50 th percentile) cost for
complex clinical visits. The median medical fees for visits of complex (CPT 99204) and
very complex (CPT 99205) clinic visits were used, because the patient cohort utilized for
the low-cost study was comprised of clinically complex patients. The complex visit is
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defined as a 45-minute visit with a median payment of $293, and very complex visit is
defined as a 60-minute visit with a median payment of $373, a meaningful payment
difference of $80 for 15 minutes. There are no assessments in the literature of clinically
meaningful cost differences in hospital admission; thus, only clinic visit cost data were
assessed using the anchor-based MID method.
4.2.2.2. Distribution-based
MIDs calculated using a distribution-based method were based on Cohen’s cutoffs
of 0.2, 0.5, and 0.8 standard deviations (SD) for small, medium, and large effect size (ES),
respectively (Cohen, 1988). Comparison ES were calculated as a percentage of mean
(5%, 10%, 20%) for small, medium, and large ES, respectively. We chose 20% as the
maximum change of the cost parameter, because that proportion is commonly used for
sensitivity analysis in economic studies to assess value of interventions (Taylor, 2009),
and our published cost effectiveness models have been shown to be robust to sensitivity
analysis employing a 20% change in cost valuation across different clinical trials and
country settings (Simpson, Baran, Kirback, & Dietz, 2011; Simpson, Jones, Rajagopalan,
& Dietz, 2007). We chose the lower percentages for this parameter to be half and one
quarter of the 20% value.
4.2.2.3. Consensus-based
MIDs calculated using a consensus-based method were based on the judgement
of professionals from various backgrounds in an academic institution that assessed cost
evaluations through a questionnaire that was administered via email. The 17 professionals
evaluating the questionnaire included 10 faculty (2 finance, 1 health services research, 2
management, 1 policy, 1 informatics, and 1 public health); and seven practitioners (2
hospital administrators, 2 medical practice managers, 1 community health center director
and 2 clinical managers). The questionnaire consisted of 4 case scenarios, two low-cost
(clinic visits) and two high cost (hospital admissions) scenarios. These scenarios included
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only mean and standard deviation parameters to mimic costs reported in general research
papers. For the visit scenarios, the mean cost reported was $335, and the standard
deviation was $237; for the two high-cost (hospital admission) scenarios, the mean cost
was $18,400 and the standard deviation was $47,900. Low-cost and high-cost each had
one scenario based on a sample size of 100 and one on a sample size of 1,000. For each
scenario, participants were asked to rate the level of cost savings (based on examples
that we derived from MID estimates $17, $35, $47, $67, $80, $120, $190 and $900, $1800,
$3600, $9600, $24000, $38000; for low-cost and high-cost respectively) as one of the
following effect sizes: trivial, small, medium, and large. This approach was not a true
Delphi method as there were no additional rounds to form a consensus. However, the
results provided narrow bands of estimates and may reflect that an underlying consensus
may be reachable with few iterations.
4.2.2.4. Power Analysis
Power to detect differences were calculated for sample sizes of 100 to 1,000.
Power was calculated using 1-sided independent t-tests for the anchor-based method and
2-sided independent t-tests for the distribution and expert-based methods, all at a 0.05
alpha level. All effect size and power were calculated using log (base 10) transformed
costs, as the costs were positively skewed and did not meet normality assumptions. All
power calculations were conducted using SAS 9.4 (Cary, NC).
4.2.3. Results
Costs for both the hospital and clinic visit studies had positively skewed
distributions (Fig. 4.2.7.1). The hospital admissions study was made up of n=6,427
patients with a mean cost of $18,418 (SD = $47,908) and a median cost of $2,591. The
clinic visit study was made up of 60-minute visits for n=421 patients with mean cost of
$335 (SD= $237) and a median cost of $237 (Table 4.2.7.1).
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4.2.3.1. Anchor-based
The anchor-based method using a meaningful payment difference of $80 between
the complex 45-minute visit and the very complex 60-minute visit represents an ES of 0.34
SD and 24% of mean costs. For consistency between graphic displays across methods,
Figure 4.2.7.2 shows the power calculations of the log transformed clinic visit costs for
sample sizes 100 to 1,000 based on the difference of $80 under the MID anchor-method
with respect to the typically minimally accepted power of 80% as indicated by the red line.
4.2.3.2. Distribution-based
Power calculations of the log transformed hospital admission and clinic visit costs,
respectively, were conducted for sample sizes 100 to 1,000 based on the small, medium,
and large ES under the MID distribution-based method on standard deviations and
percentage of mean costs. For the hospital costs, the power to detect differences for a
given sample size based on the distribution-method for MID converges to the power
needed to detect differences using the percentage of the mean (Fig. 4.2.7.3)
demonstrating the desired convergence across methods. This is encouraging and
indicates that the use of percentages and standard deviations to define MIDs may be
similar and thus could be used interchangeably or selected in a manner such that they are
most relevant or where data availability drives the choice.
In this high-cost study, we found that the distribution-based method was similar to
the method of using a percentage of mean costs. However, under these coefficient of
variance assumptions, the sample size needed for a study to be powered to detect a
difference using distribution-method of MID is the more conservative calculation when
mean cost is small, as is the case with visit costs (Fig. 4.2.7.4).
4.2.3.3. Consensus-based
Consensus-based MIDs were calculated based on the 17 questionnaire responses
received (85% returned). Two of the missing responses were due to clinicians working on
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the front line during the COVID-19 pandemic. One missing response was a faculty
member. Table 4.2.7.2 shows the average cost savings rated as small, medium, and large
effect sizes under each of the four scenarios.
The mean cost values from the surveys were calculated as a proportion of the
standard deviations and means from the scenarios (Table 4.2.7.3). Both the low cost and
high-cost proportion of SD are much smaller proportions than the 20%, 50%, and 80%
cutoffs for small, medium, and large effect size, respectively, suggested by Cohen. The
average rated cost savings among low cost clinic visits as a percentage of mean and SD
remained consistent between the two sample size scenarios, indicating that there was a
consistent estimate of what comprises a meaningful difference for low cost studies.
However, the average rated cost savings among high cost hospital admissions as a
percentage of mean and SD remained consistent only among the small and medium ES
between the two sample size scenarios. The disagreement is most observable in the large
ES as a percentage of the mean; for the smaller sample size, a large ES was considered
as much as the mean, whereas, for the larger sample size, it was almost three-quarters
of the mean.
The consistency of the proportion of SD between the scenarios of n=100 and
n=1000 is evident in the power calculations for both low and high cost as indicated by the
closeness of the solid and dotted lines within each color (e.g. green) representing the
effect size for small, medium, and large (Fig. 4.2.7.5).
4.2.4. Summary of Findings for the Three Methods
The main results for the three approaches to the specification of MID for cost
studies are shown in Figure 6 below. It appears that the distribution-based method of MID
is a usable approach for specifying effect sizes for cost studies. It may be superior to the
use of a percent decrease in mean cost for low unit cost studies, because it would guide
the researcher towards choosing a more conservative sample size estimate for measuring
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cost savings. The anchor-based method mapped almost directly to the 50% SD ES of the
distribution-based method (Fig. 4.2.7.6) and may prove to be useful if well-defined anchor
values are available. We used the difference in payment for a CPT code increment as the
anchor. However, we were not able to identify a reasonable anchor value for the hospital
admission scenario. This may limit the usefulness of the anchor method for many studies.
Several important issues emerged from our study. First, as illustrated by the power
curves in figure 6, studies that measure savings in low-cost resources, such as medical
office visits which have large variances, are rarely adequately powered for testing
hypotheses of cost differences if they have < 100 observations, unless they had lower
variability than was used in our scenarios. For these types of studies, even a “large” cost
difference determined by the distributional method is the only MID specification with > 80%
power to detect cost savings. Large sample sizes specified by the Delphi and Anchor
methods will require about 200 observations to achieve > 80% power. Studies aiming to
detect “medium” sized savings specified by the Delphi method may need at least 400
observations, and small savings may require between 800 and 1,400 observations for
adequate power. Figure 4.2.7.7 below shows similar patterns for MID estimates for the
hospital admission cost data. Only, the very high costs and large SDs make sample size
requirements much larger. Indeed, we observed that 1,000 observations are inadequate
for a study where the expected cost savings are defined by a small or medium size
difference, as determined by the Delphi method. Further, to achieve 80% power to find a
significant difference for a “small” effect defined by the distribution method may be
expected to require about 800 observations.
4.2.5. Limitations
We found that the Delphi-method MIDs were smaller than the distribution-based
MIDs (Fig. 4.2.7.6 and Fig. 4.2.7.7); however, the Delphi-method used here was not
extended for several rounds to achieve complete consensus among the respondents.
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Thus, it is possible that the Delphi-method and distribution-based MID could have
converged with further iterations. The power and sample size simulations were limited to
one study for each hospital admissions and out-patient visits. The Delphi method was
conducted on a convenience sample and did not include multiple rounds of the survey’s
results to come to a final consensus among respondents. Further simulations need to be
conducted to confirm this trend.
4.2.6. Discussion and Conclusions
Our perspective in this paper is that, for health services researchers to make
informed decisions about the value of new treatments or process improvements from a
population health perspective, we need information on changes in outcomes and costs.
Cost is a complex study variable, because it can be viewed from an organizational finance
or accounting perspective (fixed and variable costs and budget impact), or from an
economic perspective (opportunity cost or cost effectiveness). The value of specifying an
MID for cost in a study may be that it will require us to consider cost differences from both
perspectives. However, when cost is used to examine value from an economic
perspective, it should be defined as a difference in the arithmetic mean cost for the
populations treated (Glick & D, 2015). This cost measure may be expected to have a nonnormal distribution that is skewed with a long heavy right tail, and sometimes with a large
number of zero values (Glick et al, 2015 pg. 97). Standard deviations for population costs
are often equal to or even greater than their mean values. Thus, compared to the
distributions for health outcome measures, costs may be expected to require a much
greater sample size to achieve sufficient statistical power when compared to the clinical
outcomes. This poses practical as well as potentially ethical issues. From a practical
perspective, an increased sample size requirement leads to increased study costs and
perhaps also longer time before current practice is improved. This potentially deprives
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patients of better outcomes, which may be considered unethical. Further, increasing study
costs may also be considered unethical in a world of scarce resources (Williams, 1992).
In studies of program evaluation or organizational quality improvement, we may
not be able to increase sample size. This means that understanding the relationship
between study power and the definition of a MID specification for cost is important for
study planning. Given the high likelihood that the cost measure in a study greatly affects
study power, we compare our MID specification on this metric, not because it is the “best”
comparator, but because it may be expected to be the greatest constraint on the study
design and should be considered early in the study planning phase. In addition, the use
of study power as a metric for comparing different definitions of an MID illustrates to
readers the complex relationships that exist between the recommended measures of cost
(arithmetic mean and SD), sample size, and a study’s power to make inferences about the
value gained by the intervention (Glick et al, 2015 pg. 110). There are no firm criteria for
choosing a superior method for MID. Indeed, it may be desirable to use more than one
approach and examine convergence. However, three criteria should be considered: 1) the
chosen method should be relevant to decision makers, 2) the method should fit the type
of preliminary cost data available prior to the study (e.g. cannot use the anchor method if
cost data is not available for the anchor, or if an anchor that is acceptable to the major
stake holders cannot be identified), and 3) the method should reflect current benchmarks
(if any) that are available for the condition in the literature.
Additional research must be conducted to determine if the Delphi-method, when
fully implemented, agrees with the distribution and anchor-based method findings. Based
on the limited results of this small study, it appears that the anchor-based method, while
logical and simple to implement, future research should focus on identifying appropriate
anchors. It may be the case that it becomes easier to define anchors as we begin to think
in-depth about defining cost MIDs. Our thinking has evolved over the time of this study.
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When we planned this work, we could not think of a good anchor for hospital admissions.
However, now, after much discussion, we recommend that future studies of the MID for
hospital cost explore the potential value of using Diagnosis-Related Group (DRG)
incremental payment differences as MID anchors for hospital admissions. We therefore
recommend that all three methods for defining the for MID for costs be explored further
and be examined for convergence. Other issues of importance have emerged as a result
of this exploratory work. From the responses to our Delphi survey, it appears that it may
be important to examine if the absolute value of costs affect decision makers perception
of cost savings. Health services research cost studies have a number of different
audiences, and the MIDs may vary between decision-making groups. Despite the low
sample size, we observed potential clustering of responses within similarly trained groups.
MIDs defined as “Big” by clinicians, accountants, and administrators may differ. Thus,
future studies should explicitly examine if MIDs differ by current responsibility or
professional training of respondents to Delphi surveys.
4.2.7 Appendix – Tables and Figures
Table 4.2.7.1. Distribution of cost data for hospital admissions and clinic visits in USD

Hospital Admissions
Clinic Visit

N
6427
421

Mean
$18,418
$335

SD
$47,908
$237

Median (Min; Max)
$2,591 (1; 1,206,879)
$237 (50; 1,617)

Table 4.2.7.2. Results from Survey of Decision Makers in the Consensus-based
Approach: Mean (SD) Value for Survey Responses Classifying Cost Savings by Effect
Size given a Specified Sample Size (USD)
Low-Cost
Sample
Size
Effect Size
Small
Medium

100
$35 (13)
$68 (25)

1000
$43 (26)
$68 (31)

High-Cost
100
$1,920 (750)
$5,453 (3,242)

1000
$1,575 (402)
$4,388 (2,681)

62
$131
(55)

Large

$18,141
(11,989)

$120 (59)

$13,418
(10,977)

Table 4.2.7.3. Average Survey Cost Savings as proportion of standard deviation and
mean
Low-Costa
N
SD

100
Mean

Effect
Size
Small
15%
10%
Medium
29%
20%
Large
55%
39%
a
Mean = $335, SD = $237
b

SD

High-Costb
1000
Mean

18%
29%
51%

13%
20%
36%

SD

100
Mean

4%
11%
38%

10%
30%
99%

SD

1000
Mean

3%
9%
28%

9%
24%
73%

Mean = $18,400, SD = $47,900

Fig. 4.2.7.1. Histogram of hospital costs (left) and clinic visit costs (right) in US dollars

Fig. 4.2.7.2. Power calculations of log transformed hospital costs for sample sizes 1001,000 based on percentage of standard deviation and mean with 80% power level
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Fig. 4.2.7.3. Power calculations of log transformed visit costs for sample sizes 100-1,000
based on Cohen’s d suggested cutoffs and percentage of mean with 80% power level

Fig. 4.2.7.4. Power calculations of log transformed costs for sample sizes 100-1,000
based on rated cost savings as a percentage of SD for low-cost clinic visits (left) and
high-cost hospital admissions (right) with 80% power level
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Fig. 4.2.7.5. Power calculations of log transformed costs for sample sizes 100-1,000
based on rated cost savings as a percentage of SD for low-cost clinic visits (left) and
high-cost hospital admissions (right) with 80% power level

Fig. 4.2.7.6. Power calculations of log transformed visit costs for sample sizes 100-1,000
based on the anchor, distribution, and Delphi methods with 80% power level
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Fig. 4.2.7.7. Power calculations of log transformed hospital admission costs for sample
sizes 100-1,000 based on the distribution and Delphi methods with 80% power level
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MANUSCRIPT 3
Comparing cost of telehealth and in-person visits using time-drive activity-based
costing (TDABC)
4.3.0 Abstract
Background: Cost studies of telehealth and virtual visits (TH) are few and report mixed
results of the economic impact of virtual care and telehealth. Largely missing from the
literature are studies that identify the cost of delivering TH versus in-person care.
Materials and Methods: The objective is to compare cost of delivering virtual and in-person
care for a pediatric sick-visit example using a modified time-driven activity-based costing
(TDABC) approach. We examined visits before and during COVID-19 using: 1) recorded
structured interviews with providers, 2) iterative workflow mapping; 3) EHR time stamps
for validation; 4) standard cost weights for wages; and 5) clinic CPT billing code mix for
complexity weighs. We examined the variability in estimated time using a decision tree
model and Monte Carlo simulations.
Results: Workflow charts were created for the clinic before COVID-19 and during COVID19. Using TDABC and simulations for varying time, the weighted cost of clinic labor for a
sick visit before COVID-19 was $54.47 versus $51.55 during COVID-19.
Conclusions: Our TDABC approach is feasible to use under virtual working conditions;
requires minimal provider time for execution; and generates detailed cost estimates that
have “face validity” with providers and are relevant for economic evaluation.
4.3.1. Background
When the COVID-19 pandemic struck, telehealth and virtual visits (TH) became
essential for both patients and providers. The urgent need to convert in-person care to TH
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meant few health systems had time to plan and be deliberate in their TH approach. TH
programs already in place were scaled up quickly and improvisations were common. We
are now at the stage where we must make strategic decisions for a streamlined,
sustainable TH approach and identify the best opportunities for improvement. The cost
and value of TH services developed during the pandemic scale-up should inform our
choices. Unfortunately, cost/economic studies of TH are few and report mixed results of
the economic impact of virtual care and telehealth. Reports include large variations in
prices (Nguyen, 2020), increased overall cost of care due to “convenience” effect of virtual
visits (Jain & Mehrotra, 2020), and cost savings accrued from reduced travel time,
improved triage and access to timely care (Hooshmand & Foronda, 2018). These
published studies report costs from the perspective of patients, payers, and populations.
Largely missing from the literature are studies that identify the cost of delivering telehealth
versus in-person care from a provider perspective.
As healthcare costs increase at alarming rates, there is a need to have accurate
information when making decisions based on the value (cost-effectiveness) of health
interventions and health care processes. Decision makers must determine the most
efficient allocation of limited resources while delivering the best quality of care. Typically
cost analysis is evaluated using a top-down approach and may not be representative of
the true costs of care (Carroll & Lord, 2016; Zilberberg & Shorr, 2010). Nonetheless, these
costing results often guide the decision-making about health care process changes. Better
costing methods are therefore needed to provide a more accurate true cost estimate to
make better informed decisions. Time-driven activity-based costing (TDABC) is a less
frequently used micro-costing methodology that more accurately identifies costs of
production using service specific activity and resource use evaluated with patient specific
treatment times (Gammon & Cotten, 2016; Carroll & Lord, 2016; Tan, Rutten, van Ineveld,
Redekop, & Roijen, 2009). The TDABC method has been utilized to identify areas for
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process improvement, though, it has not always been cost efficient to perform (Shander,
et al., 2010). The biggest barrier to using traditional TDABC is that it is resource intensive;
requiring research staff with expertise in what to assess to be present in the clinic to
observe and record the care processes of each patient using a stopwatch to manually
collect the timing of processes and resource use.
The objective of this project was to compare the weighted labor costs of an inperson clinic sick visit before COVID-19 to the in-person and telehealth clinic sick visit
during the COVID-19 pandemic using a modified TDABC approach in a pediatric clinic.
4.3.2. Materials and Methods
We assessed cost of providing an in-person vs. mix of telehealth and in-person
sick visits for at a pediatric clinic in a suburban area. The study met institutional definition
of a quality improvement project and did not require IRB oversight. A mixed methods
approach was used for data collection and analysis to perform a modified TDABC of a sick
visit that could be assessed in a virtual environment. A sick visit was defined as a low
complexity clinic visit (CPT 99213), classified as a 15-minute face-to-face visit. Visits were
described for children between the ages of 5-9 years old. The TDABC steps included: 1)
recorded structured interviews with providers, 2) iterative workflow mapping, 3) EHR
timestamps for time validation, 4) standard cost weights for wages, 5) clinic CPT billing
code mix for complexity weights and 6) simulations to assess effects of uncertainty on
cost differences.
4.3.2.1. Interview data
Structured interviews were used to collect data to map the care process of a sick
clinic visit for an established patient age 5-9. An interview guide with five questions with
probes was used (Appendix A). Interviews were conducted by two interviewers familiar
with the workflow and EHR system. Two providers were interviewed separately: a
physician (MD) and a nurse practitioner (NP). Both interviewers were present for both
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sessions and the interviews were recorded. The recorded interviews were processed
using Rapid Qualitative Analysis (Taylor, Henshall, Kenyon, Litchfield, & Greenfield, 2018)
to develop the workflow charts. Iterative review of recordings was used to reach
agreement on clinic flow between interviewers. The resulting flow charts were reviewed
and edited as needed by providers who then gave final approval of their position-relevant
charts.
4.3.2.2. EHR data
Two independent sources of data from the clinic were used to extract time stamps
for clinic visits with CPT 99213. Mean (SD) in minute values were used to validate the
minute estimates in the clinic flow charts and to identify visits with CPT billing codes for
tests and time stamps for validating prescription-related process effects. These data were
used to estimate the mix of visits to generate complexity weights for the cost estimates.
One set of process validation data was extracted from the EPIC telehealth dashboard,
used by practice managers and telehealth personnel to monitor the processes in the clinic.
Data were extracted for all clinic pediatric patients with a low complexity clinic visit (CPT
99213) seen during September 2020. These data included the timestamps for check-in,
treatment start time, provider treatment team composition (i.e. MD or NP), record access
by each actor, and printing timestamp used by providers to present a visit summary and
care plan for patients at the end of the visit. A second data set was extracted from the
EPIC Clarity Warehouse, which included all CPT 99213 clinic visits in September 2019
and September 2020. These data were used to validate virtual visit time stamps and to
estimate in-person visit time stamps to be used for estimating visit costs.
4.3.2.3. Workflow Mapping Conventions Applied
The clinic flow mapping process for patients utilizing the clinic for a sick visit, from
signing-in at the beginning of the appointment to the conclusion of the clinic visit, began
with the review of the recorded interviews. Identification of each step in the process was
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completed along with the determination of actors (e.g. MD, NP, nurse, front desk
personnel) and approximate time in minutes to complete each step. Three workflow charts
were then developed for 1) in-person clinic visits before COVID-19, 2) telehealth clinic
visits during COVID-19, and 3) in-person clinic visits during COVID-19. For each of the
workflow charts, steps of the process (identified by a square) are organized by the order
in which they are completed. Potential additional or alternative steps are identified with
decision nodes (diamond) in the flow chart. For each step of the process, the average time
to complete is noted (contained within small circle in bottom right corner of squares), and
actors involved (color-coded) are identified and listed. The three workflow charts were
created from each interview, then the interviews were reviewed again to make edits to the
workflow charts. The two interviewers then met to review the workflow charts and both
interviewers agreed on the construction of the charts.
The workflow chart was reviewed while listening to the recorded interviews and
checked to be sure there were no missing connections and then returned to the
interviewees for verification of accuracy. Once any suggested edits were completed, the
interviewers reviewed the recorded interviews to ensure the accuracy of the workflow
charts. This process was repeated as analysis of minutes and cost were conducted. The
workflow charts generated by the MD and NP were combined to create a single clinic
process workflow chart for each visit type before and during COVID-19. To validate the
workflow process and time estimates for TDABC, EHR access during the visit were used
as a proxy for contact time of actors with the patient. EHR data from the EPIC dashboard
were used to evaluate the timestamp of record access and actors (Appendix B). This is
the step that replaces in-clinic time estimation in traditional TDABC and makes this a
modified TDABC approach.
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4.3.2.4. Workflow Cost Calculation
Using TDABC costing methods, the labor cost of care was estimated for inperson clinic visits before COVID-19 and the telehealth and in-person clinic visits during
COVID-19. Labor costs were calculated using median US salaries for each actor using
the US Bureau of Labor Statistics salary data for 2019. Total loaded salary for each
actor was calculated as median salary plus fringe benefits, equal to 35% of the median
salary. A total of 2,080 annual hours worked were assumed for a full-time employee; a
position-specific work capacity rate was applied: 1) nursing (e.g. Licensed Practical
Nurse (LPN) and Certified Medical Assistant (CMA)) and administration staff at 80%
(1664 hours) and 2) for provider (e.g. pediatrician and nurse practitioner) at 72.3% (1504
hours). The cost per minute for each actor was calculated as the total loaded salary
divided by the number of capacity hours per year divided by 60 (minutes). For process
steps that were either completed by two different actors or may potentially be completed
by two different actors, as identified in the workflow chart, a 50/50 weight was given to
each actor’s salary to estimate the cost per minute for the time in the mixed process
step.
The cost of each actor for the visit is determined by the total minutes utilized
multiplied by the cost per minute for the actor. For in-person and TH sick visit, the labor
costs across all actors are summed to determine the total labor cost of the clinic visit.
Analysis of labor cost was conducted using Microsoft Excel.
4.3.2.5. Simulations
Monte Carlo simulations were developed to mimic the variation of labor minutes
by the providers and staff, thus the variation of total labor cost, in the clinic setting. The
provider time was simulated using a Weibull distribution identified by Medicare specified
range for the visit type (Centers for Medicare and Medicaid Services, 2020). All other staff
time was modeled on a Beta PERT distribution defined by a ‘most likely’ value (estimated
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time from the flow chart) and a minimum and maximum value (±10% of the estimated
time). Median salary for actors were varied on a normal distribution with 10% of the median
salary for the standard deviation. The variation in minutes and cost per minute for actors
provided a distribution of costs across 100,000 visits for in-person visits before COVID
and telehealth and in-person visits during COVID. Simulations were conducted using
Crystal Ball software.
4.3.2.6. Final Costing and Decision Tree
EHR data extracted from EPIC Clarity warehouse were used to identify and
categorize providers to determine a provider for the same week in September for 2019
and 2020. Providers for each of the clinic visits were categorized as MD or NP. Decision
trees were constructed using the identified provider mix and delivery method mix (inperson or telehealth visit) to calculate an average weighted visit cost using the mean and
+/- 1 standard deviation estimated from the simulations.
4.3.2.7. Cost Comparison
Mean and standard deviations of forecasted visit cost estimated by simulations
were evaluated for differences between before COVID and during COVID. Minimally
important difference (MID) measured by a well-defined anchor has been identified as a
conservative effect size for low-cost studies (Dooley, Simpson, Nietert, Williams Jr., &
Simpson, 2021). The anchor-based MID was based on the relationship of clinic care costs
between the low complexity sick visit (CPT 99213), defined as a 15-minute face-to-face
clinic visit, and the moderate complexity sick visit (CPT 99214), defined as a 25-minute
face-to-face clinic visit. The median Medicare medical fee in 2017 was $125 and $184, for
low and moderate complexity visits, respectively. We selected the CPT anchored MID as
a meaningful payment difference between the two adjacent visit CPT codes which is $59.
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4.3.3. Results
4.3.3.1. Workflow Chart
Workflow charts capturing visit resource use estimates before COVID-19 were
similar in process and time. The combined workflow used an average of estimated times
for each step where times differed. Additionally, the workflow charts for each provider of
a telehealth visit during COVID-19 were almost identical. However, the workflow created
for an in-person clinic visit during COVID-19 had variations in the process. The risk of a
patient with a suspected COVID-19 infection for the in-person clinic sick visits during the
COVID-19 phase had the greatest variation which depended on need for use of PPE. We
chose to use the most conservative process for time estimates (i.e. assuming donning and
doffing PPE for each encounter instead of remaining in the same PPE all day).
Before COVID-19, the estimated time a provider was involved in the clinic visit
between treatment start time and visit summary printing was 15 minutes, however, the
addition of a laboratory test (e.g. nasal or throat swab) or prescription ordering each added
an additional minute to the clinic process (fig. 4.3.6.1). The average time for an LPN or
CMA was four minutes, however, if a laboratory test is needed then an additional 10
minutes is utilized by either an LPN or provider for specimen collection and analysis. The
total labor time varied between 19 to 31 minutes.
Telehealth clinic visits during COVID-19 involved only providers. The estimated
total labor minutes were 18, unless the provider encountered internet link issues with the
patient that required them to verify information and assist patient with the connection.
However, some telehealth visits are aborted. If it is determined during the telehealth visit
that the patient needs to be seen in-person then the telehealth visit is canceled so that the
patient does not get billed twice. However, labor costs must be counted for these visits
and allocated across all telehealth visits. This is because the provider must conduct the
telehealth assessment, schedule an in-person visit, and provide notes for the in-person
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clinic provider that will be seeing the patient. This unbilled visit takes an estimated 21
minutes of the provider’s time (fig. 4.3.6.2).
The clinic process for an in-person visit during COVID-19 for a non-COVID risk
patient is almost identical to the process before COVID-19. However, the in-person clinic
visit with a COVID risk resulted in less overall labor time due to fewer actors involved.
These visits are completed by the provider alone to reduce staff COVID exposure. For a
sick visit that does not require ordering laboratory tests or prescriptions, the estimated
labor time for the process is 18 to 19 minutes, regardless of the method of delivery or the
effect of the pandemic (fig. 4.3.6.3).
4.3.3.2. Visit Cost Calculation
Total loaded salary and cost per minute for each actor were calculated from
median US salaries (Table 4.3.6.1). Using time-driven activity-based costing methods, the
labor cost for a sick clinic visit was calculated using established workflow charts (Table
4.3.6.2). The labor costs for in-person visits before and during the pandemic were similar,
however, the process became more efficient during the pandemic and results in a slightly
lower labor cost ($56.16 vs. $54.68 for MD and $38.23 vs. $31.63 for NP, before COVID
and during COVID pandemic respectively). Though TH visits were mostly restricted to only
provider time, the provider spent almost the same time on the visit but the elimination of
additional actors resulted in lower labor costs ($54.68 to $49.61 for MD and $36.75 to
$31.63 for NP, under in-person and telehealth visits respectively).
4.3.3.3. Simulations
We used Monte Carlo simulations executed in Excel with a Crystal Ball extension
specifying 100,000 estimates to examine the effect of potential variations in minute and
costs on the estimates. Table 4.3.6.3 reports the mean and standard deviation from the
Monte Carlo simulations developed with the distribution the labor costs fit for each of the
3 workflows assessed under the MD and NP teams. For clinic visit costs before COVID,
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provider minutes varied 14.7 minutes and higher with labor costs fitting Gamma
distributions for both MD and NP visits. The distribution from the simulations for visit labor
costs for MD ranged from $36-$80 (Fig. 4.3.6.4). The clinic visit costs for Telehealth during
COVID both fit Beta PERT distributions with a lower cost range for MD visit costs than inperson visits (fig. 4.3.6.5). The estimated in-person clinic visit costs fit a Beta PERT
distribution for MD visits and a Gamma distribution for NP visits. The distribution for the
MD in-person visit costs had a slightly narrower range during COVID than before COVID
(fig. 4.3.6.6).
4.3.3.4. Final Costing and Decision Tree
The provider mix at the clinic was identified from EHR as 83.2% MD and 16.8%
NP for visits. Using this provider mix with the estimated costs, the mean weighted cost per
visit at the clinic before COVID was $54.47 with a range in costs of $47.26-$61.68 within
1 SD (Table 4.3.6.4). During COVID, the delivery method mix identified from EHR of 28.3%
telehealth and 71.7% in-person was added to the decision tree to provide an overall
weighted labor cost across both provider mix and delivery mix (fig. 4.3.6.7). The mean
weighted cost per visit at the clinic during COVID was $51.55 with a range in costs of
$44.38-$58.73 within 1 SD.
4.3.3.5. Cost Comparison
The difference in mean weighted visit costs were well below the MID of $59 that
we had specified as important for this study. A limitation of our analysis was the inability
to account for the number of TH visits that were aborted because the provider decided
that the problem warranted an in-person visit. An increase in this rate would increase the
weighted labor cost during COVID. To examine the effect of this factor we performed a
sensitivity analysis. Assuming an 80/20 mix of telehealth and aborted telehealth to inperson in the decision tree, the mean weighted visit cost during COVID would be $54.47,
the same mean weighted visit cost as observed before COVID. However, if we assume
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the addition of a 20% aborted telehealth visit to in-person visit to the decision tree resulted
in the identified 28.3/71.7 delivery method mix seen, the true delivery method would
actually have a rate of 35.5/64.5 with a mean weighted visit cost during COVID being
$54.84.
4.3.4. Discussion
This study has demonstrated that using our modification of TDABC the estimated
mean labor cost for care during the pandemic has not changed from the pre-COVID
period. This lack of change is largely due to the increased use of TH, which reduced
provider time by allowing them to perform several tasks simultaneously, such as chart
review, during their virtual encounters instead of before entering the exam room. However,
our results indicate that TH may be underutilized, and that provider organizations should
look to find an optimal mix of TH and in-person visits. Further, the mix of MD and NP
providers should be examined to assure that the optimal mix is present for the clinic’s
patient severity mix. Our TDABC approach helps inform important discussions of 1) which
TH programs to maintain; 2) how best to improve TH efficiency; and 3) which factors in a
clinic’s workflow can be changed to achieve the most efficient mix of TH and in-person
visits. Simulations can be utilized to illustrate the effect of uncertainty in estimates derived
for a modified TDABC approach. Its role is important to show the level of uncertainty
associated with specific attempts to maximize workflow efficiency. However, it is important
to use the correct distributional assumptions for the simulations or the results may be
misleading. We used the assumptions embedded in the CMS specifications of expected
ranges of minutes for a CPT code. Our simulation results replicate what CMS specifies to
be resource ranges that are acceptable for reimbursement of provider time. Thus, this
approach to choosing distributions for simulations could be useful if applied to other visit
types.
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4.3.5. Conclusion
As healthcare providers plan for sustained TH operations, our modified TDABC
approach may be helpful. It is feasible to use under virtual working conditions, requires
minimal provider time, can be implemented quickly, captures important variations in the
process of care that affect costs, and generates detailed cost estimates that have “face
validity” with providers and are relevant for process improvement and economic
evaluation. This approach also addresses the significant barrier to the practical use of
TDABC by avoiding direct observation, and replacing observed time with EHR time stamp
analysis, which reduces resources required to complete the analysis and makes it
implementable for processes that take place in our current “virtual” environment. While
no cost difference was found in this study during the pandemic, on the other side of cost
allocation that is beyond the scope of this research, is the ever evolving telehealth
reimbursement, which may also impact choice of telehealth or in-person visits.
4.3.6. Appendix – Tables and Figures
Figure 4.3.6.1. Workflow chart for in-person clinic visits before COVID-19
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Figure 4.3.6.2. Workflow chart for Telehealth clinic visits during COVID-19
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Figure 4.3.6.3. Workflow chart for in-person clinic visits during COVID-19

Figure 4.3.6.4. Distribution of Monte Carlo simulation for MD in-person clinic visit costs
before COVID-19
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Figure 4.3.6.5. Distribution of Monte Carlo simulation for MD telehealth clinic visit costs
during COVID-19

Figure 4.3.6.6. Distribution of Monte Carlo simulation for MD in-person clinic visit costs
during COVID-19

Figure 4.3.6.7. Decision Tree for in-person clinic visits during COVID-19
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Table 4.3.6.1. Median salary costs and Cost/Minute (USD) for actors in clinic care
process
Role

Median

Fringe

Salary

Loaded

Annual

Salary

Hours

Cost/Min

Pediatric MD

$175,300

$61,355

$236,655

1,504

$2.62

Pediatric NP

$109,800

$38,430

$148,230

1,504

$1.64

CMA1

$34,800

$12,180

$46,980

1,664

$0.47

LPN2

$47,500

$16,625

$64,125

1,664

$0.64

Medical Office Assistant

$36,600

$12,810

$49,410

1,664

$0.49

1

Certified Medical Assistant

2

Licensed Practical Nurse

Table 4.3.6.2. Labor costs estimated for clinic visits from workflow chart (USD)
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Visit type/Provider

Total

Total

Staff Min

Provider Min

Labor Cost

In-person with MD

13

19

$56.16

In-person with NP

13

19

$38.23

Telehealth with MD

3

18.351

$49.61

Telehealth with NP

3

18.351

$31.63

In-person with MD

10

19

$54.68

In-person with NP

10

19

$36.75

Before COVID-19

During COVID-19

1

Link and Telephone issues assessed at 5% of visits

Table 4.3.6.3. Labor costs estimated from simulation of 100,000 visits (USD)
Mean

SD

Fit Distribution

In-person with MD

57.56

7.69

Gamma

In-person with NP

39.10

4.83

Gamma

Telehealth with MD

51.03

7.56

Beta

Telehealth with NP

32.49

4.72

Beta

In-person with MD

56.09

7.69

Beta

In-person with NP

37.60

4.82

Gamma

Before COVID-19

During COVID-19

Table 4.3.6.4. Weighted labor costs forecast by Monte Carlo simulations (USD)
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1 SD

1 SD

below

above

Mean

Mean

Mean

Before COVID-19

47.26

54.47

61.68

During COVID-19

44.38

51.55

58.73

2.88

2.92

2.95

Difference
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CHAPTER 5
DISCUSSION

5.1. Conclusion
The science of costing is well developed among economists but has not circulated to
normal health services research and is especially lacking for clinical investigators
beginning to look at areas such as costs. As healthcare reimbursement continues a shift
to the value proposition, it is essential we enhance cost allocation accuracy; thus, we
should no longer consider costs and research resources in healthcare as an “other”
variable or an “other” measure. It is necessary to integrate the use of correct methods to
analyze costs using the large databases, specifying clinical trials assessing economic
outcomes to ensure they have an appropriate minimally important difference, and we must
progress toward using micro-costing to find both cost-effectiveness and examining
process innovations, such as, telehealth and use of EHR. This study showed all three
areas are essential, under described in the literature, and, even if understood within a
narrow group of economists that work in this area, the methods have not been
disseminated well.
5.2 Future Research
Additional research must be conducted for MID in costs to determine if the Delphimethod, when fully implemented, agrees with the distribution and anchor-based method
findings. Based on the limited results of this paper, it appears future costing research
should focus on identifying appropriate anchors. It may be the case that it becomes easier
to define anchors as we begin to think in-depth about defining cost MIDs. We therefore
recommend that all three methods for defining the for MID for costs be explored further
and examined for convergence. Future research that utilize simulations to illustrate the
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effect of uncertainty of estimates from larger sample sizes and variations for low-cost and
high-cost scenarios will assist in identifying any convergence of the MID methods in costs.
Other issues of importance have emerged as a result of this exploratory work.
From the responses to our Delphi survey, it appears that it may be important to examine
if the absolute value of costs affect decision makers perception of cost savings. Health
services research cost studies have a number of different audiences, and the MIDs may
vary between decision-making groups. Despite the low sample size, we observed potential
clustering of responses within similarly trained groups. MIDs defined as “Big” by clinicians,
accountants, and administrators may differ. Thus, future studies should explicitly examine
if MIDs differ by current responsibility or professional training of respondents to Delphi
surveys.
The modified TDABC approach is feasible to use under virtual working conditions;
requires minimal provider time; can be implemented quickly; captures important variations
in the process of care that affect costs; and generates detailed cost estimates that have
“face validity” with providers and are relevant for process improvement and economic
evaluation. Future research that can examine the true proportion of aborted TH visits that
were aborted because the provider decided that the problem warranted an in-person visit
could provide a more accurate weighted clinic visit cost. This approach addresses the
significant barrier to practical use of TDABC by resources required to complete the
analysis, thus, implementing the approach across multiple clinics can provide a better
assessment of an estimated delivery method mix that would optimize labor resources and
reimbursement while providing quality care. In addition, this approach to choosing
distributions for simulations could be useful if applied to other visit types.
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APPENDICES
Appendix A - Interview Guide
First, we are going to talk about a visit for a sick child, think about a child between the
ages of 5-9 that happened in the fall before we started any video visits.
Think about the process that would have normally taken place in your practice when that
child comes in.
1. How is that child’s visit scheduled?
a. How much time does it take to schedule?
2. Now the mother and child show up at the front desk, what happens?
a. Front desk clerical staff does that?
b. How much time do you think it takes staff to do that?
* Not worried about time patients sit and wait, only staff
3. Now you have an exam room free in the back, what happens?
a. What measurements are taken?
b. How much time does that take?
c. Who does the triage? E.g. CMA, nurse?
4. Now the patient is sitting in the examining room, what happens?
a. As the provider, what do you do?
i. Before you go in, do you look at a record?
1. How much time does that take?
b. Now you’re in the exam room, there’s the mother and child, what do you
do?
i. How much time does that take?
5. You are done examining the child, what happens?
a. Do you leave?
i. What do you do?
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ii. How much time does that take?
b. Do you go back into the room?
i. If so, how long does that take?
6. Then what happens?
a. End of visit?
i. Who walks them out?
ii. Check out?
1. If so, who checks them out? Clerical staff?
2. How long does that take?

7. What if the child needs a test? E.g. flu swab or strep swab
a. How does that change the visit?
b. Who does the swab? E.g. Nurse?
i. If someone else, do you talk to them?
ii. How long does the swab take?
8. The test results come back, then what happens?
a. Positive
i. Do you go back in?
ii. How long does that take?
b. Negative
i. Do you go back in?
ii. How long does that take?
9. End of visit the same?
a. If no, what happens?
Now we have the same sick visit happening under COVID.
Think about the process that normally takes place in your practice for a virtual visit.
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10. How is the child’s visit scheduled?
a. How much time does it take to schedule?
11. As the Provider, how do you know they are scheduled?
12. Is there anything you need to do before the virtual visit?
a. How long does that take?
13. What do you do if the patient is late logging onto their visit?
a. What do you work on in that time?
b. What if you have a wrong number?
i. How often do you think that happens?
14. Now you have mom on video with her child sitting next to her, what do you do?
a. How much time does the virtual exam take?
b. Do you have more often follow-ups or check-ins with virtual than when inperson?
i. How do you do a check-in?
1. How long does that take?
ii. How do you do a follow-up?
1. How long does that take?
15. Suppose you feel the child needs a test, e.g. flu swab or strep swab, or needs to
be seen in-person; what happens?
a. In-person a different provider?
i. If yes, does in-person need to reexamine?
1. Do you send notes to other provider?
16. How do you end the virtual visit?
17. Do you have anything else you need to do after the call ends?
a. How much time does that take?
When a child needs to be seen in-person following a virtual visit,
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What does the process look like?
18. Does the child check-in?
a. How long does that take?
19. When the nurse gets the child, what happens?
a. Are the nurses masked?
b. Put on PPE?
i. If yes, how long does that take?

We will turn this into 2-3 flow charts.
We will send these to you by email,
If they are fine and we haven’t made any mistakes or left anything out, then you can just
ok them by email. If there are changes, we would like to have another brief talk with you
so you can explain what we need to edit.
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Appendix B - Workflow Validation Using EHR Time Stamps
B.1 Methods
To validate the workflow process and time estimates for TDABC, EHR time stamps
for access during the visit were used as a proxy for estimating contact time of actors with
the patient. EHR data from the EPIC dashboard were extracted for one week and visually
examined for relevance in use for estimating contact minutes for the visit flow charts. We
conferred with clinical users and informatics experts on which timestamps would be
expected to most consistently capture the visit workflow and contact times of actors. The
major problem that we identified was related to the fact that no check-out time was present
in the virtual visit record. When the record indicated a change in actor, but the previous
actor did not have a log out time, the next actor’s recorded record access was used as the
end point. If the calculated time difference between record access was less than 1 minute,
1 minute of actor time was assigned. After consultations with informatics and clinical
experts, we decided to use the printing of patient advisement summary timestamp used
by the last step in the virtual visit. However, it should be noted that our finding of this lack
of a formal “check out” has resulted in the consideration of a change in the clinical process.
On examination it was found that the lack of a check out step in many cases resulted in a
failure to schedule needed follow up visits. The selection of these timestamps for our study
meant that we could not validate the minute estimates involved for the steps completed
by the medical office assistants at check-in and check-out. This is a limitation of our study,
but a minor one because the medical assistant time contribution to the care workflow is
recognized to be very short and consume a low-cost resource. The error may be expected
to be greater if we assumed that the medical office assistant’s time was used when in
actual practice the time is more likely to reflect a patient waiting for treatment to begin.
This is especially the case for those patients who check-in early.
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Clinic workflow actors were identified and categorized into groups with similar
functional and cost characteristics (e.g. MD, NP, LPN, CMA). Other actors whose time
statms were observed in the records, but who had not been identified as central actors in
the workflow specification were excluded from the not typically involved in the standard
clinic workflow were excluded from our time stamp analysis (e.g. human services). Visits
that did not have a printing time stamp were excluded from our minute validation because
the clinic visit end time could not be established. Given the positively skewed data for time
and costs, mean, median and interquartile range are reported. Analysis of the time-stamp
data was conducted using SAS version 9.4.
B.2 Results
There were 706 clinic visits available for analysis from the EHR data extract. The
overall mean clinic visit time was 22.8 minutes (SD=19.2) with an interquartile range of
10-31 minutes. This was consistent with the estimate from the validated workflow charts.
The data showed that most visits were completed by 1 to 2 unique actors (44.1% and
28.8% respectively). As the number of unique actors involved in the visit increased, the
mean time of the visit also increased.
Access times across actor categories was positively skewed so medians are
reported here. Median access time for MD’s was accurate according to workflow chart
estimates of 15 minutes. Residents had a slightly lower median access time, 11 minutes,
and nurse practitioners had the lowest median access time at 9 minutes. Median access
time for LPN was 14 minutes, which is accurate for clinic visits including lab tests. Whereas
CMA median access time was approximately 10 minutes compared to the estimated 4
minutes in the workflow chart. This discrepancy of slightly higher LPN and CMA time may
be due to not having a record log out time and result from us having to use the next access
time as a proxy endpoint. We have received qualitative confirmation that this variance is
likely the result of overestimating LPN and CMA time in the current data pull because their
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estimated time is likely to include patient wait time for the provider. We will examine this
assumption once the new checkout timestamp requirement has been implemented and
sufficient records have accumulated.
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Appendix C – Monte Carlo Simulations
Simulations can be utilized to illustrate the effect of uncertainty in estimates when data are
not available. These variations can be modeled using various probability distributions to
best simulate the variations expected in the clinic. Identification of the correct models in
the Crystal Ball software is necessary to provide accurate estimates in the simulations.
C.1 Crystal Ball Distributions
C.1.1 Weibull Distribution
The Weibull distribution can take on different forms depending on the shape parameter.
There are three parameters in Crystal Ball for the Weibull distribution that defines the
probability distribution: 1) location, 2) scale, and 3) shape. The location parameter shifts
the start of the distribution where a larger location parameter shifts the start of the
distribution farther away from the origin. The scale parameter affects the spread of the
distribution where a larger parameter would result in a broader and shorter distribution
and a smaller parameter would result in a narrower and taller distribution. While both
location and scale parameter affect the “shape” of the distribution, this does not affect the
functional form the distribution takes. A shape parameter is a special parameter for
distributions that can take on different functional forms for the distribution. A shape
parameter < 1 indicates a decreasing rate overtime, whereas a shape parameter > 1
indicates an increasing rate overtime. A shape parameter = 1 indicates no change in rate
overtime.
C.1.2 Normal Distribution
A normal distribution is a symmetric bell-shaped distribution that is often used to model
random variables. The normal distribution has two parameters: 1) location and 2) scale.
The normal distribution is a fixed form distribution that does not have a shape parameter.
The location parameter is identified by the mean and the scale parameter identified by the
variance.
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C.1.3 Beta PERT
A Beta PERT distribution is a smoother form of the triangular distribution defines the
distribution by the minimum value, maximum value, and mode. The formula for the mean
of the triangular distribution is the average of the minimum, maximum, and mode values.
This distribution assumes equal weight to the minimum and maximum values indicating
that these values are just as likely to occur as the value most frequent. In comparison, the
formula for the mean of the Beta PERT distribution weights the mode four times the
minimum and maximum values.
C.2 Simulation of Visit Cost Calculation
Monte Carlo simulations were developed to examine the effect of potential variation in
minute and cost estimates. The provider time was simulated using a Weibull distribution
identified by Medicare specified range for the visit type (Centers for Medicare and
Medicaid Services, 2020). The scale and shape of the distribution remain constant across
the delivery methods based on the distribution identified (scale = 5.5 and shape = 2.4).
However, the location had to be adjusted as each delivery method had different mean
provider time. The location for in-person visits was 14.65 and TH was 13.65. When
controlling for aborted TH visits that were required to be seen in-person, the location was
30.55 to account for the addition of the TH labor time to the in-person visit. All other staff
time was modeled on a Beta PERT distribution defined by a 10% of the estimated total
time for the minimum and maximum values. Median salary for actors were varied on a
normal distribution using a 10% of the mean for the standard deviation. This distribution
was selected due to the narrow range often accompanying salary bands for ranks held in
clinics. Simulations were then utilized to estimate total cost for the visit using the defined
variation in minutes and cost per minute for actors 100,000 trials for each of the three
workflows using Crystal Ball software. The distribution resulting form the simulations were
fit to examine the distributions of costs.

